Epstein Barr Virus Related Diffuse Large B Cell Lymphoma of the Elderly: Assessment of Frequency in an Indian Tertiary Care Centre and Comparison of the Morphological Features of the EBER-ISH Positive and EBER-ISH Negative Cases by Ananthvikas, J
  
 
EPSTEIN BARR VIRUS RELATED DIFFUSE 
LARGE B CELL LYMPHOMA OF THE 
ELDERLY- ASSESSMENT OF FREQUENCY IN 
AN INDIAN TERTIARY CARE CENTRE AND 
COMPARISON OF THE MORPHOLOGICAL 
FEATURES OF THE EBER-ISH POSITIVE AND 
EBER-ISH NEGATIVE CASES 
 
 
 
 
A DISSERTATION SUBMITTED IN PART FULFILLMENT OF THE 
REQUIREMENTS FOR THE M.D. DEGREE BRANCH III 
(PATHOLOGY)  EXAMINATION OF THE TAMIL NADU Dr. M.G.R. 
MEDICAL UNIVERSITY, CHENNAI TO BE HELD IN APRIL 2017.
 CERTIFICATE 
 
This is to certify that this dissertation titled “EPSTEIN BARR VIRUS RELATED 
DIFFUSE LARGE B CELL LYMPHOMA OF THE ELDERLY- 
ASSESSMENT OF FREQUENCY IN AN INDIAN TERTIARY CARE 
CENTRE AND COMPARISON OF THE MORPHOLOGICAL FEATURES 
OF THE EBER-ISH POSITIVE AND EBER-ISH NEGATIVE CASES” is a 
bonafide work done by Dr. Ananthvikas J, in part fulfilment of the rules and 
regulations for the M.D. Branch III (Pathology) Degree Examination of the Tamil 
Nadu Dr. M.G.R Medical University, to be held in April 2017. 
 
 
Dr. Vivi M Srivastava, MBBS, MD. 
Professor and Head, 
Department of General Pathology, 
Christian Medical College, Vellore. 
 
 
 
Principal,  
Christian Medical College, 
Vellore.
 CERTIFICATE 
 
This is to certify that this dissertation titled “EPSTEIN BARR VIRUS RELATED 
DIFFUSE LARGE B CELL LYMPHOMA OF THE ELDERLY- 
ASSESSMENT OF FREQUENCY IN AN INDIAN TERTIARY CARE 
CENTRE AND COMPARISON OF THE MORPHOLOGICAL FEATURES 
OF THE EBER-ISH POSITIVE AND EBER-ISH NEGATIVE CASES” is a 
bonafide work done by Dr. Ananthvikas J, in part fulfilment of the rules and 
regulations for the M.D. Branch III (Pathology) Degree Examination of the Tamil 
Nadu Dr. M.G.R Medical University, to be held in April 2017. 
The candidate has independently reviewed the literature, performed the data 
collection, analysed the methodology and carried out the evaluation towards 
completion of the thesis. 
 
 
 
Dr. Marie Therese Manipadam, MBBS, MD. 
Professor,  
Department of General Pathology 
Christian Medical College, 
Vellore.
 CERTIFICATE 
 
This is to certify that this dissertation titled “EPSTEIN BARR VIRUS RELATED 
DIFFUSE LARGE B CELL LYMPHOMA OF THE ELDERLY- 
ASSESSMENT OF FREQUENCY IN AN INDIAN TERTIARY CARE 
CENTRE AND COMPARISON OF THE MORPHOLOGICAL FEATURES 
OF THE EBER-ISH POSITIVE AND EBER-ISH NEGATIVE CASES” is a 
bonafide work done by me, under the guidance of Dr. Marie Therese Manipadam, in 
part fulfilment of the rules and regulations for the M.D. Branch III  (Pathology) 
Degree Examination of the Tamil Nadu Dr. M.G.R Medical University, to be held in 
April 2017. 
I have independently reviewed the literature, performed the data collection, analysed 
the methodology and carried out the evaluation towards completion of the thesis. 
 
 
 
Dr. Ananthvikas J 
Postgraduate registrar,  
Department of General Pathology 
Christian Medical College, 
Vellore.
 
 ACKNOWLEDGEMENT 
 
I express my sincere thanks to Dr. Marie Therese Manipadam, my guide and mentor 
for her constant support and her patient and calm demeanor that helped me stay 
focused throughout. I wish to express my gratitude to Dr. Auro Viswabandya from 
the department of Clinical Hematology for his prompt help and support, aiding in 
the timely completion of this thesis. I also express my thanks to Mrs. Grace, 
department of biostatistics for her help in data analysis. 
Last, but not the least, I dedicate this work to all the patients, without whose clinical 
material, this would not have been a reality
 TABLE OF CONTENTS 
RATIONALE FOR THE STUDY ......................................................................................... 1 
AIM AND OBJECTIVES...................................................................................................... 3 
AIM ................................................................................................................................... 4 
OBJECTIVES .................................................................................................................... 4 
HYPOTHESIS ................................................................................................................... 4 
REVIEW OF LITERATURE ................................................................................................ 5 
Introduction ....................................................................................................................... 6 
Epidemiology ..................................................................................................................... 8 
Clinical features ............................................................................................................... 10 
Etiopathogenesis .............................................................................................................. 11 
Epstein Barr Virus ........................................................................................................... 12 
Epstein Barr Virus and Diffuse Large B Cell Lymphoma .............................................. 19 
Morphology of EBV positive DLBCL ............................................................................ 22 
Immunophenotype of EBV positive DLBCL .................................................................. 23 
Molecular analysis ........................................................................................................... 24 
Differential diagnoses ...................................................................................................... 25 
MATERIALS AND METHODS ......................................................................................... 27 
Introduction ..................................................................................................................... 28 
Clinical parameters .......................................................................................................... 30 
Histological study ............................................................................................................ 31 
Immunohistochemistry .................................................................................................... 34 
Epstein Barr Encoded RNA In Situ hybridization (EBER-ISH) ..................................... 35 
Statistical analysis ............................................................................................................ 36 
RESULTS ............................................................................................................................ 37 
Frequency of EBV positive DLBCL in our population ................................................... 38 
Clinical features ............................................................................................................... 38 
Histologic features ........................................................................................................... 44 
Immunohistochemistry .................................................................................................... 52 
IMAGES .............................................................................................................................. 56 
DISCUSSION ...................................................................................................................... 70 
Clinical and epidemiological parameters ........................................................................ 71 
Histomorphologic analysis .............................................................................................. 76 
Immunohistochemistry .................................................................................................... 81 
The debate over an age threshold for diagnosis of EBV+DLBCL of the elderly ........... 85 
CONCLUSION .................................................................................................................... 87 
LIMITATIONS OF THE STUDY ....................................................................................... 89 
ANNEXURES ..................................................................................................................... 90 
BIBLIOGRAPHY ................................................................................................................ 94 
 LIST OF TABLES 
TABLE 1: EBV LATENCIES AND THEIR ASSOCIATED VIRAL PRODUCTS 15 
TABLE 2: AGE CHARACTERISTICS OF EBER POSITIVE AND EBER NEGATIVE CASES 39 
TABLE 3: PERINODAL EXTENSION OF TUMOUR CELL INFILTRATE IN EBER-ISH POSITIVE NAD 
NEGATIVE CASES OF DLBCL 51 
TABLE 4: PERCENTAGE OF BACKGROUND CD3 POSITIVE T CELLS SEEN IN EBER-ISH POSITIVE AND 
NEGATIVE CASES OF DLBCL 52 
TABLE 5: SUMMARY OF ALL CASES OF NODAL DLBCL IN PATIENTS >45 YEARS OF AGE AND 
COMPARISON WITH THE EBER-ISH POSITIVE CASES. 55 
 
 
 
LIST OF FIGURES 
FIGURE 1: AGE WISE DISTRIBUTION OF CASES OF DIFFUSE LARGE B CELL LYMPHOMA OLDER THAN 
45 YEARS OF AGE 39 
FIGURE 2: COMPARISON OF THE AGE AT PRESENTATION OF EBER POSITIVE AND EBER NEGATIVE 
CASES 39 
FIGURE 3: GENDER DISTRIBUTION OF ALL CASES OF NODAL DLBCL >45 YEARS OF AGE 40 
FIGURE 4: PATIENT DEMOGRAPHICS FOR ALL CASES OF NODAL DLBCL >45 YEARS OF AGE 41 
FIGURE 5: COMPARISON OF B SYMPTOMS AT PRESENTATION BETWEEN EBER-ISH POSITIVE AND 
NEGATIVE CASES 42 
FIGURE 6: CLINICAL STAGE AT PRESENTATION 43 
FIGURE 7: IPI SCORE AT PRESENTATION AMONG EBER POSITIVE AND EBER NEGATIVE CASES 43 
FIGURE 8: PATTERN OF TUMOUR CELL INFILTRATE AMONG EBER-ISH POSITIVE AND NEGATIVE 
CASES 45 
FIGURE 9: MORPHOLOGIC/ CYTOLOGIC SUBTYPES OF DLBCL AMONG EBER POSITIVE AND EBER 
NEGATIVE CASES 46 
FIGURE 10: DEGREE OF REACTIVE BACKGROUND INFILTRATE AMONG EBER-ISH POSITIVE AND 
EBER-ISH NEGATIVE CASES 47 
FIGURE 11: DEGREE OF NECROSIS AMONG EBER-ISH POSITIVE AND NEGATIVE CASES OF DLBCL
 47 
FIGURE 12: PROPORTION OF TINGIBLE BODY MACROPHAGES IN CASES OF EBER-ISH POSITIVE AND 
NEGATIVE CASES OF DLBCL 48 
FIGURE 13: PRESENCE OF INTRATUMOURAL MULTINUCLEATE GIANT CELLS 49 
FIGURE 14: INTRATUMOURAL VASCULAR PROLIFERATION IN EBER-ISH POSITIVE AND NEGATIVE 
CASES OF DLBCL 50 
FIGURE 15: INTRATUMOURAL FIBROSIS AMONG EBER-ISH POSITIVE AND NEGATIVE CASES OF 
DLBCL 51 
FIGURE 16: PERCENTAGE OF CASES WITH MILD, MODERATE AND MARKED BACKGROUND CD3 
POSITIVE T CELL INFILTRATE 52 
 
 
 LIST OF PHOTOMICROGRAPHS  
PHOTOMICROGRAPH 1: VAGUE NODULAR PATTERN! 57!
PHOTOMICROGRAPH 2: CENTROBLASTIC MORPHOLOGY! 57!
PHOTOMICROGRAPH 3: CENTROBLASTS WITH MANY IMMUNOBLASTS! 58!
PHOTOMICROGRAPH 4: ANAPLASTIC MORPHOLOGY! 58!
PHOTOMICROGRAPH 5: PREDOMINANCE OF CLEAR CELLS! 59!
PHOTOMICROGRAPH 6: MILD REACTIVE BACKGROUND! 59!
PHOTOMICROGRAPH 7: MARKED REACTIVE BACKGROUND! 60!
PHOTOMICROGRAPH 8: NECROSIS! 60!
PHOTOMICROGRAPH 9: APOPTOSIS! 61!
PHOTOMICROGRAPH 10: MULTINUCLEATE GIANT CELLS! 61!
PHOTOMICROGRAPH 11: REED-STERNBERG LIKE GIANT CELL! 62!
PHOTOMICROGRAPH 12: TINGIBLE BODY MACROPHAGES! 62!
PHOTOMICROGRAPH 13: VASCULAR PROLIFERATION! 63!
PHOTOMICROGRAPH 14: ANGIOINVASION! 63!
PHOTOMICROGRAPH 15: INTRANODAL FIBROSIS! 64!
PHOTOMICROGRAPH 16: PERINODAL EXTENSION! 64!
PHOTOMICROGRAPH 17: SCATTERED CD20 POSITIVE CELLS IN 1 CASE! 65!
PHOTOMICROGRAPH 18: >60% CD3 POSITIVE T CELLS IN A CASE WITH A MARKED REACTIVE BACKGROUND! 65!
PHOTOMICROGRAPH 19: NODULAR PATTERN OF EBER-ISH POSITIVE CELLS! 66!
PHOTOMICROGRAPH 20: DIFFUSE PATTERN OF EBER-ISH POSITIVE CELLS! 66!
PHOTOMICROGRAPH 21: SCATTERED EBER-ISH POSITIVE CELLS (50-60%) IN 1 CASE! 67!
PHOTOMICROGRAPH 22: 5% TO 10% EBER-ISH POSITIVE TUMOUR CELLS IN 1 CASE, CONSIDERED AS 
NEGATIVE! 67!
PHOTOMICROGRAPH 23: EBER-ISH POSITIVE- INTENSE BLUE STAINING OF POSITIVE CELLS ON A RED 
BACKGROUND! 68!
PHOTOMICROGRAPH 24: ARTIFACTUAL DULL BLUISH STAINING OF CELLS, NEGATIVE FOR EBER-ISH! 68!
PHOTOMICROGRAPH 25: EBER-ISH - INTENSE EDGE ARTIFACT WITH A DULL BLUISH STAINING OF 
INTERVENING TUMOUR CELLS! 69!
PHOTOMICROGRAPH 26: EBER-ISH - SAME CASE AS ABOVE SHOWING A DULL ARTIFACTUAL STAINING OF 
CELLS, NEGATIVE FOR EBER-ISH! 69!
 
 
 
 
 
 1 
 
 
 
 
RATIONALE FOR THE STUDY 
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Diffuse Large B cell lymphoma (DLBCL) is one of the commonest B Cell Non-
Hodgkin lymphomas seen in routine practice. This is a high-grade lymphoma 
requiring chemotherapy and follow-up of patients. A subset of these lymphomas 
was found to be associated pathogenetically with the Epstein Barr virus (EBV) and 
it was further demonstrated that cases of DLBCL who were positive for markers of 
EBV showed poor response to conventional chemotherapy and a more aggressive 
course of illness. Awareness of the EBV status of DLBCLs in high-risk groups such 
as elderly patients could aid in prognostication of such cases, avoiding unnecessary 
and toxic chemotherapy. 
Currently available immunohistochemical markers for EBV include EBV Latent 
Membrane Protein 1 (LMP1), which although commonly used, has its own 
limitations. The Latent Membrane Protein 1 is expressed in only two of the three 
latency phases of EBV, and interpretation could be challenging owing to the patchy, 
cytoplasmic staining characteristics.  
Epstein Barr Encoded RNA (EBER) In Situ Hybridisation (ISH) is a newer 
technique that helps improve detection of EBV RNA in tissue sections. EBER is 
expressed in all 3 latency stages of EBV. The positive signals are stained blue on a 
red background, aiding in easy identification of positives. 
Available literature on the incidence of EBV positive DLBCL (EBV+DLBCL) in 
elderly persons is predominantly from the western world and Europe, with a few 
reports from Korea, Japan and China. Currently, there is no data on the incidence of 
these EBV positive DLBCLs in India.  
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AIM AND OBJECTIVES 
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AIM 
To assess the disease frequency of EBV positive cases of nodal diffuse large B cell 
lymphoma in our setting diagnosed using the Epstein Barr Encoded RNA In Situ 
Hybridisation (EBER-ISH) technique and comparison of the morphology of EBER 
positive and EBER negative cases. 
 
 
OBJECTIVES 
1.! To identify cases of EBV positive diffuse large B cell lymphoma in patients 
older than 45 years of age in our institution during the period of January 
2009 to September 2014 using the Epstein Barr Encoded RNA In Situ 
Hybridisation technique on lymph node biopsy specimens. 
2.! To assess the disease frequency of nodal EBV positive diffuse large B cell 
lymphoma in patients older than 45 years in our setting. 
3.! To do a detailed histological study of all cases and identify morphological 
features that could be useful in suspecting EBV positivity. 
 
 
HYPOTHESIS 
The frequency of EBV positive diffuse large B cell lymphoma in patients older than 
45 years is higher in our setting than in the western population. 
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Introduction 
EBV positive diffuse large B cell lymphoma (EBV+DLBCL) of the elderly has been 
considered as a provisional entity in the “World Health Organization classification 
of tumours of haematopoietic and lymphoid tissues”, and has been defined as “EBV-
positive clonal B-cell lymphoid proliferation that occurs in patients >50 years and 
without any known immunodeficiency or prior lymphoma”.(1) The age limit of >50 
years may have been considered as these patients, owing to age related senescence 
of the immune system, tend to have defective immune surveillance for the Epstein 
Barr Virus (EBV). Initial reports suggested a predominant extra-nodal occurrence of 
this neoplasm (stomach, lung, skin, tonsils) with additional lymph node involvement, 
whereas only around 1/3rd of cases were found to involve the lymph nodes alone. 
Known cases of immunodeficiency including causes secondary to 
immunosuppression, autoimmune diseases and transplantation need to be excluded 
for a diagnosis of this entity.  
 
Epstein-Barr virus infects most people in childhood or adolescence, and usually leads 
to adaptive immunity. Infection occurring in adolescence or young adulthood leads 
to infectious mononucleosis in 35%-69% of cases. Lymphoproliferative disorders 
associated with EBV include B-cell lymphomas, T/NK cell lymphomas and HIV 
related lymphoproliferative disorders as follows.(2)  
•! EBV associated B cell lymphoproliferative disorders 
o! Hodgkin lymphoma 
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o! Burkitt lymphoma 
o! Post-transplant lymphoproliferative disorders 
o! Lymphomatoid granulomatosis 
o! Pyothorax associated lymphoma 
o! Senile EBV associated EBV positive lymphoproliferative disorders 
•! EBV associated T/NK-cell lymphoproliferative disorders 
o! Angioimmunoblastic T cell lymphoma 
o! Extranodal nasal T/NK-cell lymphoma 
o! Non Hepatosplenic γδ T-cell lymphomas 
o! Enteropathy-type T-cell lymphoma 
o! Peripheral T-cell lymphoma 
•! EBV associated HIV-related lymphoproliferative disorders 
o! Primary CNS lymphoma 
o! Primary effusion lymphoma 
o! Plasmablastic lymphoma 
  
Post-transplant lymphoproliferative disorders (PTLD) are a serious complication 
following solid organ transplantation. Majority of these cases are associated with 
EBV, and could be linked to the re-activation of dormant EBV owing to post 
transplant immunosuppression. In children, however, a majority of cases are linked 
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to primary EBV infection occurring post-transplant.(3) Recently, Gibson et al 
described “EBV positive Extranodal Marginal Zone Lymphoma of Mucosa 
Associated Lymphoid Tissue” in the post-transplant setting as a distinct entity.(4) 
According to the 2016 edition of the WHO classification of lymphoid neoplasms, 
post-transplant lymphoproliferative disorders include Plasmacytic hyperplasia 
PTLD, Infectious mononucleosis PTLD, Florid follicular hyperplasia PTLD, 
Polymorphic PTLD, Monomorphic PTLD and Classical Hodgkin lymphoma 
PTLD.(5)  
Oyama et al, in 2003, published a paper titled “Senile EBV+ B-Cell 
Lymphoproliferative Disorders” in the American Journal of Surgical Pathology, 
where they evaluated twenty-two cases of Epstein-Barr virus associated B cell 
lymphoproliferative disorders with no predisposing immunodeficiency. These 
patients had a median age of 75.5 years and were all more than 60 years old, and 18 
of these cases shows extra-nodal involvement. A few other studies on EBV+DLBCL 
have followed since, representing different geographic regions of the world and have 
shown a varying incidence of EBV positivity in cases of DLBCL of the elderly.(6–
12) 
 
Epidemiology: 
The prevalence of EBV related DLBCL of the elderly is varied according to reports. 
According to a study by Lu et al from China published in Nature in 2015, an analysis 
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of EBER-ISH positivity in 250 cases of DLBCL revealed an incidence of 15.1% in 
the elderly group and 11.9% in the younger group when they considered a threshold 
for positivity as 20%. In contrast, when a threshold for positivity of 50% was applied, 
the incidence of EBER positivity reduced to 11.4% in the elderly group and 8.3% in 
the younger group.(13) Similarly, in a study from Peru by Beltran et al comprising 
199 elderly patients of DLBCL, the incidence of EBER-ISH positivity was found to 
be slightly higher 14.9% and 9% when cut-off values of 20% and 50% respectively 
were applied.(6) Park et al, in a study on 380 cases of DLBCL from Korea, reported 
an incidence of 8.9% positivity with a cut-off of >20%.(14) 
Studies from Japan have revealed varying results. A study by Kuze et al published in 
the Japanese Journal of Cancer Research in 2000 reported an incidence of 11.4%. 
However, no mention was made about the cut-off value considered for EBER ISH 
positivity.(7) Oyama et al in 2007 reported a similar incidence of 8.7% of EBV 
positive DLBCL when a cut off of 50% was applied.(8) On the other hand, in a study 
by Wada et al published in the Journal of Medical Virology in 2011, the incidence 
was found to be much lower at 3.3% and 1% when cut-off values of >20% and >50% 
respectively were applied, and this was found to be comparable to the incidence 
reported in the western hemisphere.(15) 
A study published in Modern Pathology by Hofscheier et al compared cases of EBV 
positive DLBCL between Mexican and German populations and reported a higher 
incidence in the Mexican cohort (7%) when compared to the German cohort (2%) 
when a cut-off of >20% positivity for diagnosis was applied.(10) Similarly, Hoeller 
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et al identified a much lower incidence of 3.1% in the European population with the 
analysis being done using a tissue microarray method.(16) 
Ok et al in 2014 studied the prevalence of EBV infection in cases of DLBCL 
occurring de novo in a large multicenter cohort of 732 patients from the USA, 
Europe, China and South Korea, and found EBV positivity in 28, i.e. 4% of patients, 
with a mean age of 60.5 years. However, they included all age groups in their study, 
possibly explaining the lower mean age when compared to other cohorts.(17) 
Clinical features 
EBV+DLBCL of the elderly affects people more than 50 years of age with a slight 
male preponderance.(18) In a study published by Park et al, they found EBV 
positivity in 9% of cases, which showed a strong association with age older than 60 
years, advanced stage of disease, multiple extranodal sites of involvement, higher 
clinical international prognostication index, presence of B symptoms and a poorer 
response to therapy.(14) There seems to be no predilection for nodal or extranodal 
sites, with variable incidence reported in literature. Some of the common extranodal 
sites of involvement include skin, soft tissue, bones, stomach, tonsils, tongue, lung, 
pleura, liver, spleen, peritoneum and bone marrow. They generally tend to show an 
aggressive course of disease, and studies from Asia report a mean survival of 2 
years.(6,8–10,14,15) When CD30 is also expressed, the survival rates in cases of 
EBV+DLBCL of the elderly has been found to be worse. 
Dojcinov et al classified the spectrum of EBV positive B cell lymphoproliferative 
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diseases in adults into 4 diagnostic categories: 1) Reactive lymphoid hyperplasia; 2) 
Polymorphic extranodal lymphoproliferative disease; 3) Polymorphic nodal 
proliferative disease and 4) Diffuse Large B Cell Lymphoma. They found that the 
five-year survival decreased progressively in these groups, in contrast to the 
frequency of monoclonality that was found to increase.(11) Two recently described 
entities add to the spectrum of EBV positive lymphoproliferative disorders, including 
EBV positive mucocutaneous ulcer and Plasmablastic lymphoma of the elderly. EBV 
positive mucocutaneous ulcer is a term used to describe a small volume extranodal 
polymorphic lymphoproliferative state especially involving mucosal sites and skin, 
characterized by an indolent course of illness and a good prognosis.(19) 
Plasmablastic lymphoma of the elderly has also been studied to show an indolent 
course and overall better prognosis compared to other age related EBV positive B 
cell lymphoproliferative disorders.(20) 
Etiopathogenesis: 
The etiopathogenesis of EBV+DLBCL of the elderly has been postulated to be a 
related to immune senescence that occurs with aging. From an immunologic 
standpoint, aging results in a dysregulated relationship between inflammatory and 
inflammation neutralizing factors that results in a chronic low grade pro-
inflammatory state that could lead to lymphomagenesis. This effect may be related 
to dysregulation of critical oncogenic pathways such as p53, retinoblastoma, nuclear 
factor kB and mitogen activated protein kinases by radical oxygen species. 
Immunosenescence also refers to a continuous remodeling process where the 
 12 
adaptive immunity is preferentially affected compared to the innate immunity, with 
resultant decrease in B cell diversity with age and a concurrent clonal expansion of 
B cells in vivo. The T cell compartment also shows changes such as a reduction in 
the absolute number of total T lymphocytes including CD4+ and CD8+ cell counts, 
a progressive decrease in the naive T cell population with a decrease in the T cell 
diversity, and a progressive expansion of oligoclonal CD28- T cells, especially 
among the CD8+ T cell subset.(21,22) 
There is growing evidence to suggest a clonal expansion of dysfunctional EBV 
specific cells to age leading to the shrinkage of the T cell repertoire available for 
novel antigens. A study by Ouyang et al evaluated the frequency of CD8+ T cells 
that carried the receptors for an immunodominant EBV lytic epitope in old and young 
patients by direct staining with HLA peptide tetrameric complexes. They found a 
significantly higher frequency of EBV tetramer positive cells within the CD8+ T cell 
subset in the old compared to the young, whereas the EBV antigen specific Interferon 
gamma producing T cells were less frequent.(23) 
Epstein Barr Virus: 
The Epstein Barr virus was the first human tumour virus to be isolated, and was 
identified by Epstein and colleagues in 1964 in a cell line derived from Burkitt 
lymphoma.(24) EBV is a gammaherpes virus considered as the prototype of the 
Lymphocryptovirus genus, and is formally designated as Human Herpesvirus 4 
(HHV-4). Two major EBV types, EBV-1 and EBV-2, have been detected in humans, 
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that differ in the genetic sequence that codes for the EBV nuclear antigens.(25) The 
DNA sequence heterogeneity found when comparing specific regions of the EBV 
genome from different geographical locations could be explained by the two types 
containing different strains.(26) 
EBV is a DNA virus and contains a linear double stranded 172kb DNA molecule that 
encodes more than 85 genes. The EBV open reading frames are named based on the 
BamH1 restriction fragment on which they are found. The many EBV open reading 
frames are further classified as latent and lytic genes, further divided into immediate 
early genes, early genes and late genes.  Several of these lytic genes encode for 
human homologues, while some latent genes are non-translated. This is the case of 
EBV encoded RNA (EBER) 1 and 2.(27) The viral genome also contains a series of 
0.5 kb terminal repeats at either end and internal repeat sequences that serve to divide 
the genome into short and long unique sequence domains that have most of the 
coding capacity.(28) These terminal repeats are good markers of whether EBV 
infected cells are from the same progenitor, as the viral DNA circularizes when it 
infects a cell and persists as a circular episome with a particular number of terminal 
repeats that depends on the number of terminal repeats in the parent genome.(29) 
Humans are the only natural host for EBV. EBV, like other gamma-herpesviruses, 
can establish latent infection in lymphocytes and cause these latently infected cells 
to proliferate.(30) EBV infection of B cells is mediated through the interaction of 
viral envelope glycoprotein gp350/220 with the cellular receptor for C3d 
complement component CR2 (CD21).(31) Once the virus particle binds to the surface 
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of the host cell, it undergoes endocytosis and the viral envelope fuses with the host 
cell membrane. This process involves viral glycoproteins gp85, gp25 and gp42. Gp42 
can bind to MHC class 2 and this is used as a cofactor by EBV in the infection of B 
lymphocytes,(32) 
CD21 independent pathways may be responsible for the EBV infection of cells other 
than B lymphocytes such as T lymphoma cells and other epithelial cells including 
those seen in nasopharyngeal carcinoma, gastric carcinoma and oral hairy 
leukoplakia.(33) Current evidence suggests that EBV infection in healthy chronic 
virus carriers is restricted to B lymphocytes, and sometimes in epithelial cells that 
probably serve as sites for replication and amplification of EBV rather than a site for 
persistent latent infection. EBV survives in the host cell by establishing latency as an 
episome in memory B cells, and uses only a limited number of genes to maintain its 
genome and evade host reaction. 
The Epstein Barr virus spreads via the saliva and enters the epithelium of the 
Waldeyers ring surrounding the oropharynx and probably initiates a lytic infection 
leading to amplification of the virus. Naïve B cells in the underlying lymphoid tissue 
are then infected to become activated lymphoblasts using the growth transcription 
programme (Latency III). In this phase, the gene products expressed are EBNA -1, -
2, -3A, -3B, -3C, LP, LMP1, LMP-2A, LMP-2B and EBERs. The default 
transcription or latency II functions mainly to differentiate the activated B cells into 
memory B cells and exit the germinal centre. The gene products expressed during 
this stage are EBNA-1, LMP1, LMP-2A and EBERs. Then, the latency transcription 
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programme, i.e., latency 0, begins in the memory B cell in which all viral protein 
expression is turned off and this allows lifetime persistence. When these cells 
occasionally divide, they express the EBNA-1 only latency, i.e. latency 1. The 
memory B cells on returning to the tonsil may occasionally undergo plasma cell 
differentiation triggering viral replication. The resulting virus particles may be 
released into the saliva and further transferred to other hosts or infect other B cells. 
The different EBV latencies and their associated expression of viral products has 
been summarized below.(34) 
Table&1:&EBV&latencies&and&their&associated&viral&products&
 EBER EBNA-1 EBNA-2 EBNA-3 LMP-1 LMP-2 
Latency I + + - - - - 
Latency II + + - - + + 
Latency III + + + + + + 
 
In all forms of latency, EBV expresses two classes of non-coding small RNA (EBER 
1 & 2) that are highly structures RNAs containing 167 and 172 nucleotides 
respectively. The expression of these is restricted to the cell nucleus where they are 
present at approximately 107 copies per cell. Further, specific latency EBV-
transcription programmes have been demonstrated in many tumour. Type III latency 
is observed in patients with infectious mononucleosis or a subset of post-transplant 
lymphoproliferative disorders. Type II latency is commonly seen in classical 
Hodgkin lymphoma and a subset of post-transplant lymphoproliferative disorder. 
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Type I latency is characteristically seen in Burkitt lymphoma.(35) All these tumours 
probably originate in relation to specific stages in the EBV life cycle and are 
associated with disturbances of the immune system.(36,37) 
The prevalence of EBV is high throughout the world, as suggested by numerous 
reports, and the exposure to EBV is likely to be linked to socioeconomic 
factors.(38,39) Two major types of EBV have been identified, i.e., EBV 1 and EBV 
2, and differ in their geographic distribution, although the role of specific EBV types 
in the etiology of cancer is unknown. Immunocompromised patients generally tend 
to harbor both subtypes. The virus is generally transmitted by the oral route although 
other routes such as through transfusion have been reported. 
Following primary infection by transmission of cell free virus or infected cells via 
saliva, the virus enters the circulating B cell pool and escapes detection in most cases. 
The mucosal epithelial cells may also provide sites for intermittent viral replication. 
However, the resting memory B cells may be the true reservoir of infection, and also 
express a very restricted pattern of latent viral gene expression. Primary infection 
invariably leads to infectious mononucleosis. EBV related malignancies may arise in 
the background of viral reactivation by other cofactors. 
Detection of EBV in virus associated malignancies could either be performed on the 
tissue sections or in serum. Cell free EBV DNA has been detected in the serum of 
patients with many malignancies including Hodgkin lymphoma, post-transplant 
lymphoproliferative disease, NK/T cell lymphoma, Burkitt lymphoma and 
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nasopharyngeal carcinoma, but has not been detected in healthy carrier controls. This 
indicates that EBV DNA is not found in the serum in the absence of active EBV 
disease. Detection of plasma EBV DNA by PCR has been proposed as a sensitive 
and specific diagnostic marker for tumour diagnosis. 
Detection of EBV in tumour cells can be performed by PCR or in-situ hybridization 
using the BamH1 internal fragment of the viral genome as a probe. Recently 
however, the use of probes specific for small nuclear EBV encoded RNAs, EBER-1 
and EBER-2 which are expressed in all types of EBV infection has provided a major 
breakthrough in routine diagnosis with a high sensitivity. In cases of nasopharyngeal 
carcinoma, detection of EBV genomic DNA shows high loads.  
EBV expresses 3 latent membrane proteins during the periods of latency II and III, 
i.e., LMP 1, LMP 2A and LMP 2B. LMP 2A can also be expressed in resting virus 
carrying B lymphoblasts in healthy individuals, representing the reservoir of latent 
infection.(40) LMP 2A in combination with LMP 1 are necessary for continued 
lymphoma survival via the TRAF regulation of Nuclear Factor kB.(41) The Latent 
membrane proteins are multifunctional and are expressed on the cell membrane as 
well as intracellular membranes of the Golgi and endoplasmic reticulum. 
Latent membrane protein 1 (LMP1) although essential is not mandatory for the 
transformation of B lymphocytes into lymphoblastoid cell lines, and EBV mutants 
lacking LMP 1 fail to effectively immortalize B cells. LMP 1 is an integral membrane 
protein and acts as a constitutively activated receptor and is functionally similar to 
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the tumour necrosis factor receptor family of proteins It also leads to activation of 
nuclear factor kB, JNK kinase and JAK/STAT pathways, with a downstream effect 
of protection from apoptosis. LMP 1 causes upregulation of anti-apoptotic proteins 
such as A20 and Bcl2 and can block apoptosis. LMP 1, when expressed on epithelial 
cell in vitro blocks DNA repair and induces micronuclei formation, chromosomal 
aberrations and genomic instability.(42) 
Latent Membrane Protein 2A (LMP 2A) in vitro when studied on transgenic mice 
has been found to promote the survival of mature B cells in the absence of surface 
immunoglobulin expression. LMP 2A is essential for growth transformation of B 
cells as EBV mutants that lack the LMP 2A fail to allow germinal centre cells to 
survive. Studies on lymphoblastoid cell lines have shown that LMP 2A blocks both 
B cell receptor signaling and antigen processing functions.(43) LMP 2A has been 
suggested to have an important role in maintaining viral latency. It has also been 
found to modulate cell growth and apoptosis by activation of PI3 Kinase. LMP 2A 
can also potentially inhibit the activation of lytic EBV replication by cell surface 
mediated signal transduction. 
The EBV-encoded RNAs (EBERs) are 2 non coding and non polyadenylated RNAs 
that are always expressed in large numbers in latently infected cells irrespective of 
the phenotype. These act as regulators of signaling and transcription factors resulting 
in production of interferons and cytokines. They are also found to induce Interleukin 
10 as an autocrine growth factor in Burkitt lymphoma via retinoic acid inducible gene 
I mediated activation of IRF 3. EBER-2 via its induction of interleukin 6 has also 
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been thought to contribute to B cell transformation. 
Programmed Death Ligand 1 (PD-L1) has been studied in certain virus and 
immunodeficiency associated lymphomas. PD-L1 is an immunomodulatory 
molecule expressed by antigen presenting cells and a few tumour cells, and engages 
receptors on T cells to inhibit T-cell mediated immunity. Clinical trials on anti PD-
L1 antibodies have shown long lasting clinical response in patient with solid 
tumours.(44,45) PD-L1 has been shown to be expressed by Reed Sternberg cells of 
Classical Hodgkin lymphoma and the malignant B cells in EBV positive Post 
Transplant Lymphoproliferative Disorder.(46) Chen et al in 2013 demonstrated 
robust and strong PD-L1 expression in most cases of nodular sclerosis and mixed 
cellularity Hodgkin lymphoma, EBV positive post-transplant lymphoproliferative 
disorders, T cell rich large B cell lymphoma, EBV positive diffuse large B cell 
lymphoma, nasopharyngeal carcinoma, extranodal NK/T-cell lymphoma and HHV-
8 associated primary effusion lymphoma.(47) 
 
Epstein Barr Virus and Diffuse Large B Cell Lymphoma 
The pathogenesis of EBV+DLBCL is now understood to be a combination of 
immune senescence that further enables the proliferation and outgrowth of EBV 
infected B cell clones. This is further supported by the morphologic similarities 
between EBV+DLBCL of the elderly and immunodeficiency associated 
lymphoproliferative disorders such as PTLDs. Subclinical expansion of EBV 
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positive B cells may preclude the onset of over disease.(48) 
A study by Fagnoni et al provided further insight and evidence toward the age related 
senescence of the immune system. They studied the circulating naïve CD95 negative 
T cell reservoir throughout the human lifespan, based on the fact that the ability to 
mount a primary immune response rests on these cells. They found a sharp decrease 
in the naïve T cells with age, and the oldest individuals were almost completely 
depleted of circulating CD28 positive cells.(49) The combination of decrease in naïve 
T cells and reduction of CD8+ T cell function(23) in an exhausted immune system 
seen in the elderly may facilitate the uncontrolled proliferation of EBV positive B 
cells, and may provide an explanation to increased incidence and severity of disease 
in the elderly. 
In a study by Oyama et al, they found 32% of the cases to express EBNA2, therefore 
displaying a type III latency. This indicates a reduced immunity against EBV and is 
believed to occur only in the setting of an immunodeficiency with reduced antibody 
response to EBNA 1, EBNA 2 and EBNA-LP.(50) There was no prognostic 
difference however, between cases displaying latency type II or latency type III. It 
has been presumed that cases positive for EBNA 2 may have an additional cause of 
immunosuppression rather than just age related Immunosenescence. 
However, recent studies have brought to light the occurrence of EBV positive 
DLBCLs in younger patients as well. A study by Lu et al found that over a follow up 
period of 29 months, patients with EBV+DLBCL showed an overall survival that 
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was significantly worse in both the older and younger age groups. Further, the older 
and younger groups showed a similar overall survival and progression free survival 
with no significant difference between the two groups.(13) This was in contrast to 
another study by Hong et al who reported that EBV positive DLBCL in young adults 
was not associated with unfavorable outcomes.(51) An elegant study by Nicolae et 
al published in 2015 described 46 cases of EBV+DLBCL in patients younger than 
45 years of age. They discussed that the EBV+DLBCL in the young resembles those 
of the elderly in many respects, in that they both expressed a predominant activated 
B cell or Non Germinal B cell phenotype and had an EBV latency type II. However, 
in contrast to the elderly type, EBV+DLBCL of the young showed a clinical response 
to standard treatment protocols and showed a favorable outcome. They also found a 
higher proportion of nodal disease rather than extranodal disease, which is in contrast 
to that observed in EBV+DLBCL of the elderly.(52) 
These findings led to the questioning of the arbitrary age cut off of >50 years as 
defined by the WHO in the 2008 classification of lymphoid neoplasms. Ok et al 
studied EBV positive DLBCL in a Caucasian population and found a similar 
clinocopathologic, immunophenotypic and genetic profile in patients <50 years and 
>50 years of age. However, they found a poorer performance status in the elderly 
group. They proposed that the arbitrary cut off of 50 years for EBV positive DLBCL 
is unnecessary, and this has further been considered for implementation in the latest 
2016 edition of the WHO classification of hematopoietic and lymphoid 
neoplasms.(5,53) 
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Morphology of EBV positive DLBCL: 
Histologically, EBV positive DLBCL may present as two subtypes- Polymorphic and 
monomorphic.(54) The polymorphic subtype is more common and is shows B cells 
in varying stages of maturation including centroblasts, immunoblasts and 
plasmablasts with a background infiltrate of small lymphocytes, plasma cells and 
histiocytes. Reed Sternberg cells may sometimes be seen in the infiltrate, and may 
sometimes be prominent enough to pose a diagnostic difficulty with Hodgkin 
lymphoma. The monomorphic subtype on the other hand shows sheets of large 
transformed B cells. This distinction, however interesting, is not considered clinically 
significant. 
Other histologic features reported include large areas of geographic necrosis or 
apoptosis, both of which are considered to be important and raise a suspicion of EBV 
positive DLBCL.(18) The pattern of infiltration could vary from nodular to vaguely 
nodular and diffuse. Moreno et al reported that the predominant subtype of DLBCL 
in EBV positive cases is of the non-germinal centre/ activated B cell type.(9) In 
contrast, Park et al reported a similar proportion of Germinal centre B cell subtype in 
both EBER positive and EBER negative cases.(14) 
Nicolae et al in their study of EBV+DLBCL in patients <50 years of age recognized 
3 main histomorphologic patterns including T-cell/histiocyte rich large B cell 
lymphoma like, B cell lymphoma unclassifiable with features intermediate between 
DLBCL and Classical Hodgkin Lymphoma (Grey zone lymphoma), and DLBCL-
 23 
NOS. They also observed a higher frequency of CD30 positivity and PD-L1 
expression in the younger patients when compared to the elderly, with most cases 
exhibiting a non-germinal center B cell phenotype. 
Immunophenotype of EBV positive DLBCL 
By definition, EBV+DLBCLs show positivity for B cell antigens including CD20 
and/or CD19, CD22, CD79a, PAX5, and are negative for pan T cell markers. 
Plasmacytoid variants may show a weak positive of a negative staining for CD20. 
Immunoglobulin light chain restriction may not be demonstrable except in cases with 
immunoblastic or plasmablastic morphology where cytoplasmic immunoglobulin 
can be assessed. The activated B cell (ABC) phenotype is more common and these 
cases may show positivity for MUM/IRF4 and negative for CD10 and Bcl6. CD30 
may be positive, however CD15 is usually negative.(9,18) The Ki-67 proliferation 
index is invariably high. The neoplastic cells by definition express EBER, and 
variably express LMP1 (>90%) and EBNA2 (15-30%).(55) EBER and LMP1 show 
80%-90% concordance but are not uniformly consistent.(35) The cut-off for EBER 
positivity has not yet been clearly defined by the WHO, and many investigators have 
applied cut off values ranging from 20% to as high as 80%, with the commonest 
value being 50%.  
The proportion of EBV positivity among all cases of DLBCL increased with age, and 
this is similar to that of the ABC subtype. In view of this, it is speculated that there 
is either a change in B cell population with aging or there is a presumed pathological 
specificity of EBV in elderly patients with DLBCL.(56) 
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Molecular analysis 
The data currently available on molecular analysis of EBV positive DLBCL is 
limited. Most studies have shown a monoclonal rearrangement of Immunoglobulin 
Heavy gene (IGH).(12,50) Adam et al demonstrated B cell monoclonality in 73% of 
EBV positive DLBCL, which could be used in differentiation from cases with 
reactive atypical EBV positive lymphoproliferations in the elderly. The very little 
literature available on EBV genotype suggests an equal distribution of EBV type A 
and EBV type B among cases of DLBCL.(55) A majority of the cases of 
EBV+DLBCL of the elderly have demonstrated an activated B cell phenotype. 
Recently, it has been demonstrated that NF-κB activity is elevated in both the 
activated B cell and the Germinal centre B ell subtypes, pointing towards a potential 
use of NF-κB inhibitory therapy.(9) 
In recent times, numerous hot spot regions in the B cell receptor and Toll like receptor 
mediated NF-κB signaling have been found in cases with the activated B cell 
phenotype, while mutations of the EZH2 gene have been found in association with 
the germinal center B cell type of cases, leading to the development of targeted 
therapy in subsets of DLBCL. An interesting finding in a study by Gebauer et al was 
a slight predominance of the germinal center B cell subtype of DLBCL over the 
activated B cell subtype. They proposed that “the Hans algorithm that is widely 
employed to classify DLBCL based on immunohistochemistry, is likely to be biased 
in cases harboring an EBV infection owing to the EBV nuclear antigen 3C driven 
deregulation of IRF-4 (Mum-1)”.(57) They further proposed that EBV infection 
 25 
could lead to direct amplification of NF-κB activation through EBV LMP1 and 
LMP2A in both non-neoplastic and malignant B cells (such as in DLBCL).(9,58,59) 
Differential diagnoses: 
The spectrum of differential diagnosis of EBV positive DLBCL ranges from benign 
to malignant conditions. EBV reactivation leading to an infectious mononucleosis 
like illness in old age must be considered. The EBV associated reactive lymphoid 
proliferations are generally characterized by an expansion of the inter-follicular area 
with proliferation of small blood vessels. There is usually a mixed infiltrate of small 
lymphocytes, plasma cells and immunoblasts, some of which resemble Reed 
Sternberg cells. EBER in situ hybridization may show scattered positive cells in the 
interfollicular area. 
EBV positive Classical Hodgkin Lymphoma occurring in older patients is one of the 
most challenging differential diagnosis of EBV+DLBCL. The strong homogenous 
expression of CD20 in more than 50% of Reed Sternberg like cells, along with 
expression of B cell specific transcription factors like OCT-2 and BOB 1 favor a 
diagnosis of EBV+DLBCL over a Classical Hodgkin lymphoma.(60) The expression 
of CD30 may not be useful in differentiation. EBER and EBV LMP1 are invariably 
expressed in cases of Classical Hodgkin lymphoma of the elderly as they are more 
often associated with EBV.  The elevated number of cytotoxic T cells positive for 
TIA1 and/or Granzyme B, amounting to more than 30% of the background infiltrate 
is also a feature in favor of EBV+DLBCL of the elderly.(54) 
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Plasmablastic lymphoma invariably manifests in extranodal sites, and is more often 
secondary to immunodeficiency states. Morphologically, it is characterized by a 
diffuse proliferation of large cells morphologically resembling centroblasts and 
plasmablasts but immunophenotypically resembling plasma cells. Tumour cells are 
usually negative for CD20 and variably express IRF4/MUM1, CD138 or CD 79a. 
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MATERIALS AND METHODS 
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Introduction 
This study was performed in the department of general pathology, Christian 
Medical College, Vellore. Cases were retrieved from the Oracle based electronic 
database using a key-word search. It was observed that approximately 50% of cases 
were of DLBCL involving the lymph node, among which there was an almost equal 
proportion of cases less than 45 years of age and more than 45 years of age. We 
adopted an age criteria of 45 years based on available literature.(52,53,61,62) 
A literature search was then performed for EBV positive DLBCL of the elderly, and 
the reported incidence in each study was noted. The statistician then helped us 
calculate a sample size of 138 cases with a 95% confidence level that was based on 
the existing prevalence in published literature, the expected prevalence in our 
setting and the average number of cases reported in our department. 
The institutional review board and ethics committee of the Christian Medical 
College, Vellore, approved this study (IRB Reference number 9144 dated 12-11-
14). 
All cases of lymph nodal DLBCL diagnosed between January 2009 and September 
2014, in patients older than 45 years, were identified from the electronic database of 
the department of General pathology. The available clinical discharge summaries 
and laboratory investigations on the electronic hospital information system database 
were analysed and relevant clinical and serological data was collected.  
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Inclusion criteria: 
•! Cases of lymph nodal diffuse large B cell lymphoma occurring in patients 
older than 45 years of age 
 
Exclusion criteria: 
•! Patients with a documented positive infectious serology test for any of the 
blood borne viruses 
•! Patients less than 45 years of age at the time of biopsy 
•! Patients who were either on treatment or had received treatment for 
lymphoma 
•! Cases of diffuse large B cell lymphoma with features suggestive of a grey 
zone lymphoma (features intermediate between DLBCL and Burkitt 
lymphoma) or a double hit lymphoma 
•! Cases with an initial presentation of DLBCL involving an extranodal 
site/organ with subsequent spread to lymph nodes 
•! If paraffin blocks were not available 
•! If paraffin blocks were available but contained very tiny or absent tissue 
fragments, insufficient for further evaluation 
 
The first 129 consecutive cases of nodal DLBCL that fulfilled the above criteria 
were then selected for the study. The initial sample size of 138 was calculated 
assuming an incidence of 10% in our population with a 95% confidence level. 
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However, we were able to retrieve only 129 cases owing to unavailability of blocks 
or scanty tissue in the archived blocks. This final sample size of 129 was 
subsequently checked for power, which was found to be satisfactory at 99.99% and 
was hence considered adequate for the present study. 
 
Clinical parameters: 
Patient demographics: Patient demographics details including the age, gender and 
state of residence were noted 
 
Site of biopsy: The site of lymph node biopsy was noted, including the presence of 
multiple lymph node involvement at presentation. 
 
Clinical stage, B symptoms and IPI score: The clinical stage, presence or absence of 
B symptoms, and the international prognostic index (IPI) score for each patient as 
recorded in the discharge summaries or outpatient notes by the clinical hematologist 
were noted. 
 
Presence of marrow involvement at presentation: In those cases, where a bone 
marrow trephine biopsy was done at presentation, the presence or absence of 
lymphoma involving the marrow was noted. 
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Histological study: 
The available Hematoxylin and Eosin stained sections of 129 cases selected for the 
study were studied. Those slides that had poor preservation of staining or other 
artifacts were re-stained or re-mounted accordingly. The slides were initially 
reviewed for the ten histologic parameters by the candidate, and then further 
reviewed by both the candidate and the guide together on a double-header 
microscope. This combined review helped in eliminating observer bias. 
The following were the histological parameters evaluated, and the observations 
were recorded in a Microsoft Excel® worksheet 
 
Pattern: The architecture of the tumour as seen on a low power objective was 
broadly categorized as diffuse and vaguely nodular. Among the cases that showed a 
combination of these patterns, the major and minor patterns were noted accordingly. 
Any deviation from these patterns was noted accordingly. 
 
Subtype: Cases of DLBCL were categorized based on morphology as per the “2008 
WHO classification of tumours of hematopoietic and lymphoid tissues” into 
centroblastic, immunoblastic and anaplastic variants. Centroblastic pattern was 
defined as those cases with a mixed population of centroblasts and immunoblasts, 
where immunoblasts amounted to <90% of tumour cells. Among these cases, those 
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that showed a relatively higher proportion of immunoblasts, but not amounting to 
90% were noted. The immunoblastic pattern was defined as those cases with a 
mixed population, where the immunoblasts predominated and amounted to >90% of 
tumour cells. The anaplastic variant of DLBCL was defined as those cases which 
showed a population of large to very large, round, oval or polygonal cells that 
displayed bizarre pleomorphic nuclei.  
 
Reactive background: A reactive background was composed of the background 
non-tumoural lymphocytes and any inflammatory cells including neutrophils and 
eosinophils. The reactive background was graded as absent, mild/focal presence 
when restricted to a few high power fields, readily evident when it was easily 
visible at a 100x magnification and marked reactive background when it obscured 
the tumour cells. 
 
Necrosis: Necrosis of tumour cells, either confluent, focal or involving individual 
cells, was noted, and was classified as absent, focal necrosis or individual cell 
necrosis when it was restricted to a few high power fields and readily identifiable 
foci or confluent when it was identifiable in many low power fields. 
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Tingible body macrophages: The presence or absence of tingible body macrophages 
between the tumour cells was noted, and categorized as absent, very few or focally 
present when limited to a few high power fields and readily apparent cells. 
 
Multinucleate giant cells: The presence or absence of multinucleate giant cells was 
identified and classified as absent or present. Cases with presence of multinucleate 
giant cells were further sub-classified as those with and without a Hodgkin Reed-
Sternberg cell like morphology. 
 
Vascular proliferation: The presence or absence of vascular proliferation was noted 
and classified as absent, focal or mild when visible only in a few high power fields 
and readily apparent vascular proliferation. 
 
Angioinvasion: The presence or absence of angioinvasion as defined by tumour 
cells infiltrating the wall of a vessel was noted. 
 
Fibrosis: The presence and the degree of intratumoural fibrosis was assessed and 
classified as no fibrosis, focal or mild fibrosis when limited to a few high power 
fields and readily evident fibrosis when easily visible on low power examination. 
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Perinodal extension: Perinodal extension, as evidenced by the presence of tumour 
cells in the perinodal adipose tissue classified as absence and presence. Those cases 
where perinodal extension was not readily apparent on initial hematoxylin and eosin 
sections, but which was detected on CD20 immunohistochemistry, were also 
considered as positives. 
 
Immunohistochemistry: 
Most cases had been worked up for CD3, CD20 and MIB-1. The archived slides 
were retrieved and examined as described below. For cases where slides were 
unavailable, the details as recorded in the database were considered. 
 
CD3: The proportion of CD3 positive reactive T cells in the background was noted 
and graded as absent, <30%, 30-60% and >60%. 
 
CD20: The presence / absence of CD20 staining was noted. 
 
MIB-1: The MIB-1 proliferation index was counted at 400x magnification and 
expressed as percentage of tumour cells staining positive. The highest proliferation 
index found is each case was noted. 
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EBV-LMP1: EBV LMP1 immunohistochemistry was available in 7 cases. The 
presence or absence of EBV LMP1 positivity among tumour cells in these cases 
was noted. 
Epstein Barr Encoded RNA In Situ hybridization (EBER-ISH): 
In situ hybridization for EBER was performed using commercially available 
reagents sourced from Ventana Medical systems Inc. These reagents principally 
comprised of the “INFORM EBER probe” and the “ISH iVIEWBlue” detection kit. 
All tests were performed on a Roche Ventana Benchmark XT automated platform.  
The standard EBER staining protocol for in situ hybridization as recommended by 
Ventana medical systems was used. A brief summary of the protocol is provided in 
the annexures.  
After checking the archived paraffin embedded blocks for adequacy of tissue, 
sections were cut on Poly-L-lysine coated slides. 3 sections were accommodated on 
each slide owing to financial constraints. For every batch of slides that were stained, 
a control was included which was a known case of EBV positive DLBCL with 
documented positivity for EBV-LMP1 immunohistochemistry. 
All stained slides were examined by the candidate at first, and then by both the 
candidate and the guide together on a double-header microscope in order to 
eliminate observer bias. Each case was evaluated for percentage positivity and the 
pattern of staining for EBER-ISH. 
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Statistical analysis: 
Frequencies were calculated for each of the clinical and morphologic parameters. A 
Chi Square test and Fisher’s exact test were used to compare the features of EBER 
ISH positive and EBER ISH negative cases to assess for significance. All statistical 
analysis was performed using the SPSS Version 16.0 software for Windows. 
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RESULTS 
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A total of 796 cases of DLBCL were diagnosed in the department of 
pathology, CMC Vellore between January 2009 and September 2014. 246 out of 
these primarily involved the lymph node. 263 out of the 796 were from patients 
more than 45 years of age.158 cases satisfied our inclusion criteria of nodal DLBCL 
in patients more than 45 years. Of these, 129 cases were retained for this study after 
elimination of 29 cases, 28 of which had inadequate tissue on paraffin blocks for 
further in-situ hybridization studies, and one case that was seropositive. The clinical 
and microscopic features were analysed in 129 cases.  
The EBER-in situ hybridization test was performed on 114 of these cases. 5 of these 
cases showed an overwhelming background artifactual staining and therefore could 
not be assessed. 7 cases were positive for EBER-ISH, with >20% of cells staining 
positive. 1 case showed a few positively staining cells, ranging between 5-10%. 8 
cases showed very occasional positively staining cells. Positivity for EBER-ISH in 
our study was considered as >10% tumour cells staining positive. 
 
Frequency of EBV positive DLBCL in our population: 
EBER-ISH staining was performed on 109 of the 129 cases, and was found to be 
positive in 7 of these. The calculated frequency of EBV+DLBCL in patients older 
than 45 years of age in our study was 6.42%. 
 
Clinical features: 
Age: The mean age at diagnosis of the cases of lymph nodal DLBCL in our study 
was 60.5 years, with the youngest patient being 47 years of age (Range 47-83 years) 
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Among the 7 cases that were positive or EBER-ISH, the mean and median age were 
found to be 65.8 years and 63 years (Range 50-82 years) in contrast to those cases 
negative for EBER-ISH that showed a slightly lower mean and median age of 60.2 
and 59 years (Range 47-83 years). 
Table 2: Age characteristics of EBER positive and EBER negative cases 
Variable Mean Median Minimum Maximum 
EBER positive 65.85714 63 50 82 
EBER negative 60.53922 61 47 83 
* EBER- Epstein Barr Encoded RNA 
 
Figure 1: age wise distribution of cases of Diffuse Large B cell lymphoma older than 45 years of age
 
Figure 2: Comparison of the age at presentation of EBER positive and EBER negative cases 
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Gender: Overall, cases of lymph nodal DLBCL showed a male preponderance 
(2.07:1). All 7 cases that showed positivity for EBER-ISH were males. 
  
Figure 3: Gender distribution of all cases of nodal DLBCL >45 years of age 
 
Patient demographics: The following chart depicts the geographical distribution of 
all cases evaluated in this study. The distribution of cases of DLBCL in our study 
reflected the demographics of patients who visit our hospital. There was no 
geographical predilection for EBV positive DLBCL seen in our study. 
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Figure 4: Patient demographics for all cases of nodal DLBCL >45 years of age 
 
B symptoms: 76 cases had documented presence/absence of B symptoms in the 
patient records; including 6 EBER-ISH positive cases and 70 EBER-ISH negative 
cases. 5 out of the 6 (83.3%) EBER-ISH positive cases had B symptoms at 
presentation in contrast to 29 of 70 (58.5%) EBER-ISH negative with B symptoms 
at presentation. 
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Figure 5: Comparison of B symptoms at presentation between EBER-ISH positive and negative cases 
 
Clinical stage: On review of the discharge summaries and out patient records, 61 
out of the total 129 cases had documented clinical stage, including 6 out of 7 
EBER-ISH positive cases and 55 of 102 EBER-ISH negative cases. Three cases 
each of EBER-ISH positive DLBCL were stage III and stage IV clinically.  
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Figure 6: Clinical stage at presentation 
International prognostication index (IPI) score: 38 of the total 129 cases had a 
documented IPI score, 4 of which were EBER-ISH positive cases. The distribution 
of IPI scores between the two groups is as depicted below. 
 
Figure 7: IPI score at presentation among EBER positive and EBER negative cases 
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Bone marrow involvement at presentation: Of the total 129 cases of DLBCL in 
patients older than 45 years of age in our study, 92 cases had undergone a bone 
marrow biopsy at presentation. This included 6 EBER-ISH positive cases and 86 
EBER-ISH negative cases. 1 among the 6 EBER-ISH positive cases and 17 among 
the 86 EBER-ISH negative cases showed bone marrow involvement by lymphoma 
at presentation. 
 
Histologic features: 
Pattern of lymphoma infiltrate: The pattern of lymphoma infiltrate in lymph node 
biopsy sections was assessed based on the architecture at low power microscopic 
examination. This was broadly classified as diffuse and vaguely nodular. Cases that 
had a mixture of both patterns were further graded based on the relative proportion 
of the vaguely nodular pattern. 5 of the 7 (71.4%) cases of EBER-ISH positive 
DLBCL showed a diffuse pattern, while a mixed diffuse and nodular pattern and a 
vaguely nodular pattern were seen in 1 case each respectively.  
Among the 102 EBER-ISH negative cases of DLBCL, 80 (78.4%) showed a diffuse 
pattern, 14 (13.7%) showed a vague nodular pattern and 6 (5.8%) showed a mixed 
diffuse and nodular pattern. 1 case in addition showed many scattered cells on 
biopsy, with no recognizable pattern. The pattern could not be recognized in 1 case. 
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Figure 8: Pattern of tumour cell infiltrate among EBER-ISH positive and negative cases 
 
Morphologic subtype: The cytologic subtypes of DLBCL that were identified in our 
study were centroblastic and anaplastic. The Immunoblastic pattern as defined by 
the WHO classification (>90% immunoblasts) was not seen. However, a subset of 
cases showed a predominantly centroblastic pattern but with increased proportion of 
immunoblasts not amounting to 90%. The other peculiar patterns observed included 
a centroblastic pattern with many clear cells and one with many spindled cells. The 
relative distribution of these patterns among EBER-ISH positive cases and EBER-
ISH negative cases is depicted in the chart below. 
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Figure 9: Morphologic/ Cytologic subtypes of DLBCL among EBER positive and EBER negative cases 
 
Reactive background: A reactive background was seen in all 7 EBER-ISH positive 
cases of DLBCL, with one case showing a marked prominence. Among the EBER-
ISH negative cases, 9 cases showed no reactive background, 40 cases showed a 
focal/ mild reactive background of which 1 case had a prominent eosinophilic 
infiltrate, and 52 cases had a readily evident reactive background, 2 of which 
showed marked prominence. The reactive background could not be assessed in one 
of the negative cases. 
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Figure 10: Degree of reactive background infiltrate among EBER-ISH positive and EBER-ISH negative cases 
 
Necrosis: Necrosis was assessable in 6 EBER-ISH positive cases and 100 EBER-
ISH negative cases. 2 of 6 (33.3%) positive cases showed frank  
necrosis. 20 of the 100 EBER-ISH negative cases showed frank necrosis and 28 
EBER-ISH negative cases showed focal minimal or individual cell necrosis. 
 
Figure 11: Degree of necrosis among EBER-ISH positive and negative cases of DLBCL 
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Tingible Body macrophages: Tingible body macrophages were evident in 4 of 7 
(57.2%) and focally seen in 1 of 7 (14.2%) of EBER-ISH positive cases. In 
comparison, of the 102 EBER-ISH negative cases, 27 (26.5%) showed readily 
evident tingible body macrophages and 26 (25.6%) showed few/occasional tingible 
body macrophages. This difference was found to be statistically significant with a p 
value of 0.03. 
 
Figure 12: Proportion of tingible body macrophages in cases of EBER-ISH positive and negative cases of DLBCL 
Multinucleate giant cells: Multinucleate giant cells were seen in 6 of 7 EBER-ISH 
positive cases, 1 of which showed a Hodgkin Reed Sternberg cell like morphology. 
Among the 102 EBER-ISH negative cases, multinucleate giant cells were seen in 47 
cases, of which 12 showed a Hodgkin Reed Sternberg cell like morphology. 
0
10
20
30
40
50
60
EBER,ISH!positive EBER,ISH!negative
Pe
rc
en
ta
ge
'o
f'c
as
es
Tingible'body'macrophages
Absent
Few/Occasional
Present
 49 
 
Figure 13: Presence of intratumoural multinucleate giant cells 
 
Vascular proliferation: Vascular proliferation was present in all 7 cases of EBER-
ISH positive DLBCL in our study. Among the 102 EBER-ISH negative cases, 77 
cases showed prominent vascular proliferation and 13 cases showed only focal 
vascular proliferation. Vascular proliferation could not be assessed in 1 case. 1 case 
in addition showed prominent hyalinization of blood vessels. 
This difference was found to be statistically significant with a p value of <0.01 
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Figure 14: Intratumoural vascular proliferation in EBER-ISH positive and negative cases of DLBCL 
 
Angioinvasion: Angioinvasion was seen only in 3 cases of DLBCL in our study, all 
of which were negative for EBER-ISH. 
 
Fibrosis: Tumoural fibrosis was seen only focally in two cases of EBER-ISH 
positive DLBCL in this study. Among the 102 EBER-ISH negative cases, tumoural 
fibrosis was readily evident in 27 cases, and only focally seen in 24 cases. Fibrosis 
could not be assessed in 3 of the EBER-ISH negative cases. 
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Figure 15: Intratumoural fibrosis among EBER-ISH positive and negative cases of DLBCL 
 
Perinodal extension: Perinodal extension of tumour cells could be assessed in 4 of 
the 7 EBER-ISH positive cases and 80 of the 102 EBER-ISH negative cases. All 4 
EBER-ISH positive cases and 76 of the remaining 80 EBER-ISH negative cases 
showed perinodal extension. 
Table 3: Perinodal extension of tumour cell infiltrate in EBER-ISH positive and negative cases of DLBCL 
 Present Absent Not assessable 
EBER-ISH positive 4 0 3 
EBER-ISH negative 76 4 22 
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Immunohistochemistry 
 
CD3: slides for CD3 IHC were unavailable in 13 cases, including 3 which were 
EBER-ISH positive and 10 which were EBER-ISH negative. The remaining cases 
of EBER-ISH positive DLBCL showed <30% CD3 positive cells in 1 case, 30%-
60% in 2 cases and >60% in 1 case. Among the remaining 92 cases of EBER-ISH 
negative cases, <30% CD3 positive cells were seen in 62 cases, 30% to 60% in 22 
cases and >60% in 8 cases. 
Table 4: Percentage of background CD3 positive T cells seen in EBER-ISH positive and negative cases of DLBCL 
 <30% 30%-60% >60% N/A 
EBER-ISH positive cases 1 2 1 3 
EBER-ISH negative cases 62 22 8 10 
 
 
Figure 16: Percentage of cases with mild, moderate and marked background CD3 positive T cell infiltrate 
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CD20: The pattern of CD20 positive B cells closely reflected the morphologic 
patterns of tumour cell infiltrates seen on the initial Hematoxylin and Eosin stained 
slides.   
 
MIB-1 proliferation index: The MIB-1 immunohistochemistry slides were 
unavailable in 2 cases including 1 each of EBER-ISH positive and negative cases. 
The average MIB-1 proliferation index in the EBER-ISH positive group was 84.2% 
(Range 75% - >95%) and that in the EBER-ISH negative group was 80.8% (Range 
40% - >95%). 
 
EBV-LMP1: EBV-LMP1 immunohistochemistry was done on 7 cases, including 3 
EBER-ISH positive cases and 4 EBER-ISH negative cases. Among the EBER 
positives, one case was negative for EBV-LMP1 while the other two cases showed 
focal and prominent positivity respectively. The four cases, which were EBER-ISH 
negative, were also negative on EBV-LMP1 immunohistochemistry. 
 
EBER-In Situ Hybridisation: EBER-ISH could be performed on 115 of the total 129 
cases, of which 5 cases showed overwhelming background artifact and hence could 
not be assessed. 7 cases showed positivity for EBER-ISH, with one case containing 
20-30% positive cells, 2 cases containing 50-60% positive cells, 1 case containing 
60-70% positive cells and 3 cases with 80-90% positive cells. One case showed 5-
10% positive cells, and this was considered as a negative case. Very occasional 
positive cells were seen in 8 cases, which were all considered as negative for 
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EBER-ISH. The positive cells could be easily identified at low power examination. 
The EBER-ISH positive cells showed a diffuse pattern in 3 cases, a nodular pattern 
in 2 cases and dispersed pattern in 2 cases. 
 
Table&5:&Summary&of&EBER>ISH&positive&cases&
Case no. Percentage EBER-ISH 
positive 
Pattern of EBER-ISH 
positive 
1 50-60 Dispersed 
2 80-90 Diffuse 
3 80-90 Diffuse 
4 80-90 Nodular 
5 60-80 Diffuse 
6 20-30 Dispersed 
7 50-60 Nodular 
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Table 6: Summary of all cases of Nodal DLBCL in patients >45 years of age and comparison with the EBER-ISH 
positive cases. 
 
Histologic feature 
Number (Percentage) 
of cases of all 
DLBCLs where 
present 
Number (Percentage) 
of EBER-ISH 
positive DLBCLs 
where present 
Pattern 
a.! Diffuse  
b.! Nodular 
c.! Diffuse and vague 
nodular 
 
99 (85) 
5 (4) 
13 (11) 
 
5 (71.4) 
1 (14.3) 
1 (14.3) 
Subtype 
a.! Centroblastic 
b.! Anaplastic 
c.! Centroblastic with 
increased immunoblasts 
d.! Centroblastic with many 
clear cells 
 
105 (85) 
4 (3) 
10 (8) 
 
5 (4) 
 
4 (57.2) 
- 
2 (28.6) 
 
1 (14.2) 
Reactive background 
a.! Focal 
b.! Readily evident 
 
56 (44.8) 
57 (45.6) 
 
 
7 (100) 
Necrosis  
a.! Focal 
b.! Readily evident 
 
38 (29.5) 
24 (18.5) 
 
 
2 (33) 
Tingible body macrophages  
a.! Focal 
b.! Readily evident 
 
37 (28.9) 
32 (25) 
 
 
5 (71.5) 
Multinucleate giant cells 56 (45.2) 6 (85.7) 
Reed Sternberg like giant cells 15 (11.6) 1 (14.3) 
Vascular proliferation  
a.! Focal 
b.! Readily evident 
 
25 (19.5) 
87 (69) 
 
 
7 (100) 
Angioinvasion  3 (2.2) 0 
Fibrosis  
a.! Focal 
b.! Readily evident 
 
28 (22) 
32 (25.2) 
 
2 (28.6) 
 
Perinodal extension 87 (69) 4 (100)- [3 cases 
could not be 
assessed] 
 
 56 
 
 
 
 
IMAGES 
 57 
 
Photomicrograph 1: H&E, 40X- Vague nodular pattern 
 
 
Photomicrograph 2: H&E, 400x, Centroblastic morphology 
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Photomicrograph 3: H&E, 400x, Centroblasts with many immunoblasts 
 
Photomicrograph 4: H&E, 400x, Anaplastic morphology 
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Photomicrograph 5: H&E, 200x, Predominance of clear cells 
 
Photomicrograph 6: H&E, 200x, Mild reactive background 
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Photomicrograph 7: H&E, 100x, Marked reactive background 
 
Photomicrograph 8: H&E, 100x, Necrosis 
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Photomicrograph 9: H&E, 400x, Apoptosis 
 
Photomicrograph 10: H&E, 400x, Multinucleate giant cells 
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Photomicrograph 11: H&E, 400x, Reed-Sternberg like giant cell 
 
Photomicrograph 12: H&E, 100x, Tingible body macrophages 
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Photomicrograph 13: H&E, 200x, Vascular proliferation 
 
Photomicrograph 14: H&E, 200x, Angioinvasion 
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Photomicrograph 15: H&E, 200x, Intranodal fibrosis 
 
Photomicrograph 16: H&E, 100x, Perinodal extension 
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Photomicrograph 17: 100X- Scattered CD20 positive cells in 1 case 
Photomicrograph 18: 100X- >60% CD3 positive T cells in a case with a marked reactive 
background 
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Photomicrograph 19: EBER-ISH, 40X-Nodular pattern of EBER-ISH positive cells 
 
Photomicrograph 20: EBER-ISH, 40X-Diffuse pattern of positive cells 
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Photomicrograph 21: EBER-ISH, 40X-Scattered EBER-ISH positive cells (50-60%) in 1 
case 
&
Photomicrograph 22: EBER-ISH, 100X-5% to 10% EBER-ISH positive tumour cells in 1 
case, considered as negative 
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Photomicrograph 23: EBER-ISH, 400X-EBER-ISH positive- Intense blue staining of 
positive cells on a red background 
 
Photomicrograph 24: EBER-ISH, 400X-Artifactual dull bluish staining of cells, negative 
for EBER-ISH 
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Photomicrograph 25: EBER-ISH, 40X-Intense edge artifact with a dull bluish staining of 
intervening tumour cells 
&
Photomicrograph 26: EBER-ISH, 400X-Same case as above showing a dull artifactual 
staining of cells, negative for EBER-ISH 
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Ours is possibly the first study on EBV+DLBCL in a cohort of patients older 
than 45 years of age from the Indian subcontinent as per our knowledge after a 
thorough literature search. The existing literature points to a varying incidence of 
EBV+DLBCL of the elderly, as well as a varying median age of patients in 
different geographic locations.(6,8–10,35,50,63,64) The exact reason behind a 
geographic variation has yet to be elucidated, although socioeconomic status and 
endemicity of EBV have been proposed as possible mechanisms. 
In a study by Arora et al from the same institute, Non Hodgkin lymphomas 
accounted for 78% of all lymphomas over a 10-year study period, among which B 
cell Non Hodgkin lymphomas were by far the commoner subgroup. Diffuse Large 
B cell lymphoma, not otherwise specified, was the commonest type of B cell Non 
Hodgkin lymphoma, accounting for almost 47% of all Non Hodgkin lymphomas.  
 
Clinical and epidemiological parameters 
Frequency of EBV+DLBCL in patients older than 45 years of age: 
We calculated a frequency of 6.42% for EBV positive DLBCL in our cohort of 
patients older than 45 years of age. This was comparable to that reported in patients 
from Turkey, Mexico and Saudi Arabia.(10,65,66) The frequency in our cohort is 
higher than that reported in the European countries and one study each from Korea 
and Japan.(10,15,16,67) On the other hand, a much higher incidence of EBV 
positive DLBCL has been reported from Japan, Korea and Peru.(6–8,14) 
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Age of patients 
The median age of EBV+DLBCL cases in our study was found to be 63 years with 
an age range of 50-82 years, and that of the EBV negative group was 61 years with 
an age range of 47-83 years. This was found to be much lower than that reported by 
other investigators. A case series from Peru by Beltran et al reported a slightly older 
median age of 75 years, ranging from 51 to 95 years.(6) A multicenter study in 2012 
by Montes-Moreno et al reported a similar slightly higher mean age of 69 years, 
with a range of 48-91 years.(9) Chi Young Ok and group also reported a higher 
median age of 71 years in their cohort of patients.(35) An earlier study by Oyama et 
al from Japan in 2003 reported a median age of 75.5 years and a range of 60-88 
years, in a cohort of 22 patients.(50) A lower median age of EBV positive DLBCLs 
was reported by Hoeller et al from Switzerland, with a median age of 67 years 
although they included all age groups and not just patients older than 50 
years.(16)Hofscheier et al in 2011 compared the geographic prevalence of 
EBV+DLBCL of the elderly in German and Mexican populations and found a 
significantly lower median age of 66 years (range 51-75 years) in the Mexican 
cohort when compared to the German cohort who showed a median age of 77 years 
(range 63-88 years). They further observed an increased proportion of cases that 
showed a small population of cells staining positive for EBER (<20%), possibly 
representing unrelated EBV transformed cells, or a secondary EBV infection of an 
already established B cell clone.(10) Possibilities for an earlier age of onset of EBV 
related lymphoma in these populations include a lower socio-economic status with 
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accompanying lower standards of healthcare, endemicity to EBV and also racial 
differences. More recently, EBV positive DLBCL has also been demonstrated in 
immunocompetent patients less than 45 years of age, and these cases have been 
shown to have a better prognosis.(51,52) Ok et al in 2015 compared cases of 
EBV+DLBCL in patients more than 50 years of age and less than 50 years of age, 
and found that both groups had similar clinicopathologic, immunophenotypic and 
genetic features, and tests on gene expression and microRNA profiling did not 
reveal and distinction between the two groups. They further suggested that the 
arbitrary age cut off for EBV+DLBCL as suggested by the WHO was unnecessary, 
and ought to be eliminated.(53) 
 
Gender 
All the cases of EBV+DLBCL in patients older than 45 years were males in our 
study. The available literature also suggests a male preponderance in these cases 
similar to our study, although our male: female ratio is much higher than that 
reported in literature which averages 1.4:1 to 1.5:1.(9,10,16,35,50) 
 
Demographics 
Ours is a tertiary care super-specialty hospital, which caters to a large part of the 
population from Eastern and Southern India, and this has been reflected in 
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outpatient demographics. We did not observe any specific or significant geographic 
variation in the EBV positive cases of DLBCL. We had initially expected a slight 
increased prevalence of EBV+DLBCL in patients from the northeastern states of 
India, based on previous studies on the geographic variations of nasopharyngeal 
carcinoma in India and a study on the sero-epidemiology of EBV in Indian 
population.(68–70) Whether a larger sample size would have demonstrated a 
geographical variation is not known. 
 
B symptoms 
B symptoms were seen in 5 out of 6 cases of EBV positive DLBCL (83%) and in 29 
of 70 cases of EBV negative DLBCL (58.5%). This was similar to the higher 
occurrence of B symptoms at presentation in EBV positive DLBCL as reported by 
Oyama et al and Beltran et al.(6,8) 
 
Clinical stage at presentation 
In our study, the clinical stage was available for 6 of the EBV positive cases, and all 
of these presented at a higher Ann Arbor stage (III and IV), in comparison to the 55 
EBV negative cases of DLBCL of whom 33 presented at a higher clinical stage 
(60%). Our findings in both groups are relatively higher than those reported by 
studies from Peru, Germany, Mexico, Japan and the USA among others, although 
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the finding of a more frequent higher stage at presentation in EBV positive DLBCL 
is consistent with currently available literature.(6,8–10,64) 
 
IPI score 
38 of the total 129 cases had a documented IPI score, 4 of which were EBER-ISH 
positive cases. 3 (75%) of the EBV positive cases of DLBCL had a high 
intermediate or more IPI score of > 3 in comparison to the EBV negative cases 
where 21 of 34 cases (61%) showed an IPI score of > 3. Oyama et al from Japan 
reported a similar distribution of cases and found a higher IPI in EBV positive cases 
when compared with the EBV negative cases of DLBCL, i.e., 54% and 37% 
respectively.(8) Beltran et al reported IPI scores of >2 in 57% of EBV positive 
DLBCL in their series from Peru.(6) The general consensus is that of a higher IPI 
seen in cases of EBV positive DLBCL when compared to the EBV negative 
counterpart.(9,50,51) 
 
Bone marrow involvement at presentation 
92 of the 129 cases in our study had undergone a bone marrow biopsy at the time of 
diagnosis, including 6 of the EBV positive cases and 86 of the EBV negative cases. 
Of these, 1 EBV positive case (16%) and 17 EBV negative cases (19%) showed 
bone marrow involvement by lymphoma. This is in contrast to a series by Beltran et 
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al who documented extranodal involvement at presentation in 11 of 28 cases (39%) 
of EBV+DLBCL, of which 2 cases (7%) showed involvement of the bone marrow. 
A study by Oyama et al in Japan showed extranodal involvement in 33% of 
EBV+DLBCL and 28% of EBV negative DLBCL, a difference that was not found 
to be statistically significant. 
 
Histomorphologic analysis 
 
Pattern of infiltrate and cell morphology 
A majority of the cases of DLBCL in our study showed a diffuse pattern, i.e., 5 of 7 
cases (71.4%) of EBV+DLBCL and 80 of 102 EBV negative DLBCL (78%).A 
vaguely nodular pattern was evident in 1 case of EBV+DLBCL and 11 cases of 
EBV negative DLBCL (14.3% and 10.7% respectively). A frank nodular pattern 
was far less common, being seen in 1 of the EBV positive cases and 3 of the EBV 
negative cases. These findings were in contrast to those described by Montes-
Moreno et al, who found a predominantly nodular to vaguely nodular pattern in a 
majority of their cases, with the diffuse pattern accounting for a smaller 38% of 
EBV positive cases.(9)The centroblastic subtype was the commonest morphology 
seen in cases of DLBCL, including 4 of the 7 EBV positive cases (57.2%) and 83 of 
102 EBV negative cases (81.3%) of DLBCL. Two of the seven cases (28.5%) of 
EBV positive DLBCL showed an increased proportion of immunoblasts, in contrast 
to the EBV negative group where an increase in immunoblasts was seen in 10 of 
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102 cases (9.8%). These findings concur with those reported in literature.(6,9,64) 
The presence of increased number of immunoblasts or cells with plasmacytoid 
differentiation have been described previously as common features of EBV positive 
DLBCL and has been said to aid in the morphological identification of EBV 
positivity in cases of DLBCL.(9,11,50,54,71) 
 
Reactive background 
A reactive background was seen in all 7 cases of EBV positive DLBCL, including 1 
case that had a marked and prominent background infiltrate of small lymphoid cells 
and plasma cells.  Among the EBV negative cases of DLBCL, 40 cases showed a 
focal or mild reactive background, including 1 case that had a prominent infiltrate 
of eosinophils. 52 of the 102 EBV negative cases (51%) showed a readily 
identifiable reactive background, of which 2 cases showed a marked prominence. 
Most investigators have variably described the presence of a reactive background as 
a polymorphous population of lymphocytes. The finding of a prominent reactive 
background in our study in all EBV positive cases concurs well with the finding of a 
polymorphous population of cells in most cases of EBV positive DLBCL in other 
studies.(6,8–10,35,64) 
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Necrosis 
Frank necrosis was found in 2 of 6 EBV positive cases (33.3%) and in 20 of 100 
EBV negative cases (20%) of DLBCL in our study. Necrosis could not be assessed 
in 3 cases. This is similar to the percentage of cases with necrosis seen in a study by 
Hofscheier et al.(10) Other researchers have, however, reported a larger proportion 
of cases of EBV positive DLBCL showing necrosis, including many cases with 
large areas of geographic necrosis.(6,18,63,64,72) 
 
Tingible body macrophages 
Tingible body macrophages were present in 5 of 7 cases (71.4%) of EBV positive 
DLBCL, being only focally seen in one of these cases. The EBV negative DLBCLs 
showed a lesser proportion of cases with tingible body macrophages, i.e. 53 of 102 
cases (51.9%), being only focally present in 26 of these. A variable proportion of 
histiocytes have been described in a few other series, although a significant 
difference has not been described between EBV positive and negative 
DLBCLs.(6,8,12,35,50) 
 
Multinucleate giant cells 
Multinucleate giant cells were seen in 6 of the 7 (85.7%) EBV positive DLBCL 
cases, one of which also showed Hodgkin Reed Sternberg like cells. 47 of the 102 
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(46%) EBV negative cases showed multinucleate giant cells, 12 of which also 
showed Hodgkin Reed Sternberg like cells. The presence of multinucleate giant 
cells, especially with a Reed Sternberg like morphology in cases of EBV positive 
DLBCL has been described in most other studies. Beltran et al found scattered Reed 
Sternberg like cells in almost all cases of EBV positive DLBCL in their series.(6) 
Giant cells including those with a morphologic resemblance to Reed Sternberg cells 
were found in 15 of 22 cases (68%) of EBV positive cases in a series by Oyama et 
al from Japan, and in 3 of 9 cases (33%) in a series by Hofscheier et al from 
Mexico.(10,50) A significant population of multinucleate giant cells with a variable 
proportion of Reed Sternberg like cells has also been described in a couple of other 
studies.(9,11,35,63,72) 
 
Vascular proliferation 
Vascular proliferation was evident in all 7 cases of EBV positive DLBCL in our 
study, and in 77 of the EBV negative cases of DLBCL. A further 13 cases of EBV 
negative DLBCL showed only focal mild features of vascular proliferation. These 
features however, have not been categorically evaluated in other studies. 
 
Angioinvasion 
Angioinvasion was not seen in any of the EBV positive cases of DLBCL in our 
study, and only seen in a minority of the EBV negative cases (3 of 102). 
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Angioinvasion per se has not been evaluated in most case series, however 
angiocentricity and an angiodestructive pattern was described in a few cases in 2 
case series by Oyama et al.(8,50) 
 
Fibrosis 
In our study, 2 of the 7 EBV positive cases of DLBCL showed a focal mild fibrosis. 
In contrast, fibrosis was seen in 51 of the 102 EBV negative cases of DLBCL, 
including 24 cases where it was only focally present. Fibrosis, like vascular 
proliferation has not been categorically evaluated in available literature. There was 
no significant association between the degree of intranodal fibrosis and the EBV 
status. 
 
Perinodal extension 
Perinodal extension could not be assessed in 25 cases, including 3 EBV positive 
cases and 22 negative cases of DLBCL. All the remaining 4 cases of EBV positive 
DLBCL showed perinodal extension, along with 76 of the remaining 80 cases of 
EBV negative DLBCL. 
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Immunohistochemistry: 
CD3 
Slides of CD3 immunohistochemistry were available in 4 of the EBV positive 
DLBCL cases and 92 of the EBV negative cases. The percentage of background 
CD3 positive T cells among the EBV positive cases was <30% in 1 case, 30-60% in 
2 cases and >60% in 1 case. Among the 92 EBV negative cases of DLBCL, CD3 
positive cells were seen up to 30% in 62 cases, 30-60% in 22 cases and >60% in 8 
cases. Although the background CD3 positive T cell population has seldom been 
quantified or characterized in other studies, this possibly correlates with the 
prominent inflammatory background that is generally seen in cases of EBV positive 
DLBCL.(8,50) 
 
CD20 
Patterns of CD20 positivity have rarely been studied in cases of EBV positive 
DLBCL. We found the pattern of CD20 positive cells to reflect the morphologic 
pattern of the tumour cells as seen on the initial Hematoxylin and Eosin stained 
sections. There was no statistically significant difference in the pattern of infiltrate 
between the EBER-ISH positive and EBER-ISH negative cases of DLBCL in our 
study. 
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MIB-1 proliferation index 
The slides of MIB-1 immunohistochemistry were unavailable in 1 case each of 
EBV positive and EBV negative DLBCL. The mean MIB-1 proliferation index in 
EBV positive cases was slightly higher (84.2%, Range 75% - >95%) than the EBV 
negative cases of DLBCL (80.8%, Range 40% - >95%), although the median MIB-
1 index was 85% in both groups. This difference however may not be accurate 
enough for comparison as we performed an approximate estimation of the MIB-1 
index and did not exactly quantify the positive cells. The Ki67 index is generally 
considered to be high in cases of DLBCL, although a significant difference has not 
been established in the EBV positive subset of cases.(35) Montes-Moreno et al 
reported a Ki67 index of >50% in 40/45 (80%) of their cases, while Beltran et al in 
their study found a median Ki67 of 80%, with a range of 50%-90% among EBV 
positive DLBCLs.(6,9) 
 
EBV-LMP1 immunohistochemistry 
EBV-LMP1 immunohistochemistry slides were available in 7 cases, 3 of which 
were EBER-ISH positive. One of the EBER-ISH positive cases was negative on 
EBV-LMP1 immunohistochemistry, while the other two cases showed a focal and a 
prominent positivity. All the four cases of EBER-ISH negative DLBCL were 
negative on EBV-LMP1 immunohistochemistry. This disparity in detection of 
Epstein Barr Virus by EBV-LMP1 immunohistochemistry and EBER in situ 
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hybridization is known, and described in literature. Montes-Moreno reported EBV-
LMP1 positivity in only 37 of 44 (84%) cases which were EBER-ISH positive.(9) 
Oyama et al found EBV-LMP1 positivity in 67 of the tested 71 cases (94%) in their 
series form Japan.(8) It is generally regarded that the concordance rate between 
EBV-LMP1 and EBER-ISH can reach up to 80%-90%, although this figure is not 
uniformly consistent. In our experience, we found it easier to identify positive cells 
on an EBER-ISH stained slide when compared to an EBV-LMP1 IHC stained slide, 
the latter which sometimes showed a patchy or weak cytoplasmic staining. 
 
EBER In Situ Hybridisation 
EBER In Situ hybridization could be performed on 114 of the total 129 cases, of 
which 5 cases showed overwhelming background artifactual staining and hence 
could not be reliably assessed. 7 cases showed >20% positive tumour cells, 3 of 
which showed positively staining tumour cells ranging between 50%-80% and 3 
cases showed >80% positive tumour cells. 1 case showed 5%-10% positive tumour 
cells, while 6 other cases showed very occasional positively staining tumour cells. 
We considered a threshold of 10% or more positive tumour cells for a positive 
result. All the positive cells could easily be identified at low power examination 
(100x magnification), owing to the excellent contrast provided by the intense dark 
blue staining of the positive cells on a red background. We observed focal to diffuse 
and faint artifactual nuclear staining in a few cases, with the nuclei staining a dull 
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bluish-red hue. All the cases that showed an artifactual background staining 
precluding interpretation were core biopsies. We presume that this may be related to 
formalin fixation of small cores of tissue, as even some of the resected lymph nodes 
showed a varying degree of edge artifact, i.e. a non-specific diffuse band of staining 
at the edge of the biopsy. 
Sasikala et al from Chennai investigated the “prevalence of Epstein Barr virus 
infection and its association with p53 expression” in a group of 87 previously 
untreated Non Hodgkin lymphomas. They reported detection of EBV in11 of 46 
cases of DLBCL, which were not restricted to any age group.(73) This apparently 
higher prevalence of EBV in DLBCL in their series could be due to the detection 
technique used, i.e. PCR. Polymerase chain reaction has been reported to have a 
relatively high sensitivity. Lymphomas are generally composed of a highly 
heterogeneous population that may include non-tumoural EBV infected cells such 
as EBV positive memory cells or normal non tumour bystander 
lymphocytes.(74,75) 
Immunohistochemistry for EBNA-2 and LMP-1 is easy to use and readily available, 
although its slightly lower sensitivity compared to other methods, ambiguity in 
evaluation of the results and inter-observer and intra-observer variability may cause 
certain issues. The use of a highly sensitive technique such as polymerase chain 
reaction also requires careful attention to avoid contamination from the saliva of the 
examiners, as EBV is ubiquitously present, and may lead to false positive results. In 
situ hybridization, on the other hand, detects EBER-1 that is expressed even during 
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latent infection, and has the advantage of visualizing a latent infection of EBV in 
tumour cells on histological sections. Furthermore, owing to the relatively large 
numbers of EBER-1 copies in the cell, the degeneration of mRNA that occurs 
during routine formalin fixed paraffin embedded tissue processing is negligible.(34) 
EBER-ISH is the currently recommended standard investigation for detection of 
EBV, for a diagnosis of EBV+DLBCL of the elderly. Although there is no definite 
consensus on the minimum percentage of positive tumour cells for diagnosis, most 
available research is based on a cut off value of >10% or >20% positive tumour 
cells(35). This variation in cut off values for EBER-ISH positive cells has been 
shown to affect the reported disease prevalence by a few researchers.(14,15,67) 
 
The debate over an age threshold for diagnosis of EBV+DLBCL of the elderly 
The WHO in 2008 had recognized an entity termed as “EBV positive Diffuse Large 
B cell lymphoma of the elderly”, which was a subset of DLBCLs that were believed 
to occur in elderly patients who had a defective immune surveillance for Epstein 
Barr Virus, owing to immune senescence. These cases were known to be resistant to 
conventional chemotherapy and hence had a worse prognosis. However, in the 
recent past, there has been an increasing body of research describing a subset of 
DLBCL cases in younger individuals that show EBV positivity. Hong et al 
compared EBV positivity in cases of DLBCL from patient >50 years and <50 years, 
and found a higher prevalence of EBV positivity in the older group. Further, 
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EBV+DLBCL in the elderly group was more closely associated with unfavorable 
clinical characteristics such as more advanced stage, higher IPI, two or more sites of 
extra-nodal involvement and so on. A poor prognostic impact of EBV positivity was 
also seen only in the elderly group and not in the younger group. There was no 
significant difference in the prognosis between the EBV positive and the EBV 
negative groups of DLBCL in younger patients. They suggested the recognition of 
“EBV positive DLBCL in young adults” as a distinct clinic-pathologic entity.(51) 
A study by Ok et al in 2015 evaluated the clinicopathologic, immunophenotypic and 
genetic features in Caucasian patients with EBV+DLBCL <50 years of age, and 
compared these to patients who had EBV+DLBCL and were >50 years of age. They 
also reported that the older patients more often had a poorer performance status. 
However, both groups were found to have similar clinicopathologic, 
immunophenotypic and genetic features. Further, gene expression profiling and 
microRNA profiling of tumours in both groups were not distinct. Based on these 
findings, they suggested the removal of the arbitrary cut off of 50 years for the 
definition of EBV+DLBCL. 
In view of these recent findings, the 2016 classification of hematopoietic and 
lymphoid tumours by the WHO has substituted the modifier “elderly” in “EBV 
positive DLBCL of the elderly” with “not otherwise specified”.(5) The designation 
of NOS emphasizes that there are more specific entities in which EBV positive 
large B cells can be found, such as in Lymphomatoid granulomatosis.  
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CONCLUSION 
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•! The frequency of EBV positive Diffuse Large B Cell Lymphoma in patients 
older than 45 years of age in our setting is 6.42% which is higher than that 
reported in the European cohort, but much lower than that reported from 
Japan, Korea and Peru. This is comparable to the reported incidence from 
Mexico, Turkey and Saudi Arabia. 
•! The average age of patients with EBV positive DLBCL in our cohort was 
65.8 years which is much lower than the global average age of presentation 
of 71 years. The earlier age of presentation was comparable to a cohort from 
Mexico with an average age at presentation of 66 years. 
•! Among the histomorphologic features, the presence of vascular proliferation 
and increased number of tingible body macrophages were found to be 
significant features in the EBV positive cases of DLBCL. These features 
could be used to triage cases of DLBCL for EBER-ISH. 
•! Edge artifacts and non-specific background staining for EBER-ISH were 
seen more often in core biopsies, possibly due to problems related to 
formalin fixation. Whether a tweaking of the fixation time for lymph node 
core biopsies corrects this issue without affecting other routine histochemical 
and immunohistochemical stains and molecular pathology work-up, needs to 
be evaluated. 
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LIMITATIONS OF THE STUDY 
•! This study included only nodal cases of Diffuse Large B cell lymphoma, and 
the calculated frequency reflects only this subset of cases. 
•! EBV-LMP1 was not available in all cases, hence a comparison with EBER-
ISH could not be done. 
•! There was no follow up of patients for assessment of response to therapy.!
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ANNEXURES 
IRB APPROVAL LETTER 
 DATA COLLECTION PROFORMA 
 
Serial number:  
 
Age:      Address (State): 
 
Gender: 
 
Site of lymph node:    Bone marrow involvement 
 
B symptoms:      Present   Absent 
 
Clinical Stage:     IPI Score 
 
Histology: 
 
Pattern of infiltrate:    Diffuse     /      Vague Nodular     /    Others 
Subtype:     Centroblastic    / Immunoblastic    /   Anaplastic 
Reactive background:   Absent     /     Mild or focal     /    Readily evident 
Necrosis:    Absent / Focal or individual cell/ Readily evident 
Tingible body macrophages: Absent    /    Few or focal    /     Readily evident 
Multinucleate cells   Present   Absent 
 If present, Reed Sternberg type  Yes  No 
Vascular Proliferation  Absent    /    Mild or focal    /     Readily evident 
Angio-invasion      Present   Absent 
Fibrosis    Absent     /     Mild or focal     /    Readily evident  
Perinodal extension   Present   Absent 
Other features if any: 
 
Immunohistochemistry 
Markers CD3 CD20 MIB-1 
percentage +ve and pattern if any    
 
EBV-LMP1 (If available):  
 
EBER-ISH staining:  Percentage:   Pattern: 
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PROTOCOL FOR EBER-ISH STAINING ON THE VENTANA BENCHMARK 
XT PLATFORM 
 
•! Warm slide and incubate for 4 minutes at 750C 
•! Apply EZPrep volume adjust and rinse (X 3) and add coverslip 
•! Warm slide to 760C and incubate for 4 minutes 
•! Rinse and disable heater 
•! Rinse and adjust slide volume with reaction buffer, apply coverslip 
•! Warm the slide to 370C and incubate for 4 minutes, rinse with reaction buffer 
•! Add One drop of ISH-Protease 2, apply coverslip and incubate for 8 minutes 
•! Rinse and adjust slide volume with reaction buffer, apply coverslip 
•! Apply One drop of INFORM EBER, apply coverslip and incubate for 4 
minutes 
•! Warm slide to 850C and incubate for 12 minutes 
•! Warm slide to 570C and incubate for 4 minutes 
•! Incubate or 1 hour 
•! Rinse slide with 2X SSC buffer (X 3), and then adjust volume with reaction 
buffer 
•! Apply One drop of iVIEW ANTI-FLUOR, apply coverslip and incubate for 
20 minutes 
•! Rinse and adjust volume with reaction buffer (X2) 
•! Apply One drop of iView blue SA-AP, apply cover slip and incubate 15 
minutes 
•! Rinse slide with reaction buffer 
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•! Apply One drop of iVIEW BLUE ENHAN, incubate for 4 minutes 
•! Apply one drop of iVIEW BLUE NBT BCIP, incubate 32 minutes 
•! Rinse and adjust volume with reaction buffer (X2) 
•! Add one drop of red counterstain, rinse and wash with SSC buffer and 
reaction buffer! !
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70
-
80 - 0 
2 
west 
bengal 
5
3 m level 5 cervical 0 - - 0 diffuse centroblastic 1 2 0 1 1 2 0 2 1 1 diffuse 
80
-
90 - 0 
3 
west 
bengal 
5
1 m right inguinal 1 IIIB - 0 
vague 
nodular, 
sinusoidal anaplastic 0 0 0 1 1 2 0 2 1 1 diffuse 
70
-
80 - 0 
4 bihar 
6
1 m para aortic 1 - - 0 diffuse centroblastic 0 0 2 0 0 0 0 2 1 1 diffuse 
60
-
70 - 0 
5 nepal 
5
2 m left cervical 0 - - 0 diffuse centroblastic 0 2 2 0 0 2 0 2 1 1 diffuse 95 - 0 
6 
jharka
nd 
5
5 m right inguinal 0 
III 
AES - 0 diffuse centroblastic 0 0 2 1 0 0 0 0 N/A 1 diffuse 
>9
5 - 0 
7 
jharka
nd 
6
5 f 
left 
supraclavicular 1 IBE - 0 diffuse centroblastic 2 0 2 0 0 2 0 1 1 1 diffuse 50 - 0 
8 kerala 
5
2 m retroperitoneal 1 IIAX 
2
/
5 0 diffuse centroblastic 2 0 0 0 0 2 0 2 1 2 diffuse 90 - 0 
9 
tamil 
nadu 
5
7 m left cervical 0 IV 
2
/
5 1 diffuse anaplastic 1 0 2 1 0 0 0 0 1 1 diffuse 90 - 0 
10 
jharka
nd 
6
3 m retroperitoneal 0 - - - diffuse centroblastic 2 0 0 0 0 2 0 1 1 2 diffuse 
60
-
70 - 0 
11 
uttarkh
and 
6
2 m right inguinal - - - 0 
vague 
nodular centroblastic 2 1 0 1 1 1 1 0 1 3 
loose 
aggregates 
60
-
70 - 0 
12 
tamil 
nadu 
7
4 m axillary 1 IIIB - 0 diffuse centroblastic 1 0 2 1 0 2 0 1 1 1 diffuse 95 - 0 
13 
madhy
a 
prades
h 
5
8 f left cervical 0 - - - 
diffuse+no
dular centroblastic 1 0 0 0 0 2 0 2 minimal 1 diffuse 80 - 0 
14 kerala 
6
2 m 
posterior 
cervical 0 IIIBX - 0 diffuse centroblastic 1 0 0 0 0 1 0 1 1 1 diffuse 80 - 0 
15 
west 
bengal 
6
6 m right axillary 0 IIIAE - 0 diffuse centroblastic 1 1 0 1 0 0 0 0 1 1 diffuse 95 - 0 
16 
west 
bengal 
6
5 f right axillary - - - 0 diffuse centroblastic 2 1 2 0 0 1 0 1 1 1 diffuse 90 - 0 
17 
jharka
nd 
6
6 m 
left 
submandibular 1 
IIIA
X 
2
/
5 0 diffuse centroblastic 2 1 1 0 0 2 0 1 1 1 diffuse 90 - 0 
18 
tamil 
nadu 
7
2 f retroperitoneal 1 - - - diffuse centroblastic 0 0 2 0 0 2 0 2 1 1 diffuse 
>9
5 - scant 
19 
west 
bengal 
4
8 m left cervical - - - - 
diffuse+no
dular centroblastic 0 2 0 1 0 2 0 2 0 1 diffuse 
>9
0 - 
occasional 
scattered 
cells 
20 
tamil 
nadu 
6
1 f left axillary 1 
IVB
X 
4
/
5 0 diffuse anaplastic 1 1 1 1 1 2 0 0 N/A 2 diffuse 
N/
A 
occasion
al 
positive 0 
21 
west 
bengal 
6
1 m left axillary 1 IVB 
5
/
5 1 diffuse centroblastic 1 0 1 1 1 1 0 1 N/A 
N
/
A 
nodular/scatter
ed 
70
-
80 negative 50-60 
22 
tamil 
nadu 
5
5 f 
right post 
auricular 0 IE - 0 diffuse centroblastic 2 0 2 1 1 2 0 2 1 3 diffuse 
60
-
70 - 0 
23 
tamil 
nadu 
7
2 m right cervical 1 IIIB 
4
/
5 0 diffuse centroblastic 1 2 2 1 0 1 0 0 N/A 1 diffuse 
>9
0 - 0 
24 
west 
bengal 
7
0 f left cervical - - - - diffuse centroblastic 1 0 2 1 1 2 0 0 1 1 diffuse 
>9
0 - 0 
25 
tamil 
nadu 
8
2 m 
right 
submandibular 0 IVX 
3
/
5 0 diffuse centroblastic marked 0 1 0 0 1 0 0 N/A 1 diffuse 
>9
5 - 80-90 
26 
tamil 
nadu 
7
1 f right cervical 0 IIE 
3
/
5 0 diffuse centroblastic 1 0 2 1 0 2 0 2 1 1 diffuse 90 - 0 
27 
west 
bengal 
4
7 m right cervical 0 - - - 
vague 
nodular anaplastic 1 0 2 1 1 2 0 1 1 1 diffuse 70 - 0 
 28 assam 
6
4 m left axillary 1 - - - diffuse centroblastic 1 2 2 0 0 2 0 2 1 1 diffuse 90 - 0 
29 assam 
5
2 f left cervical - - - - diffuse centroblastic 1 2 0 1 0 0 1 2 1 1 diffuse 
>9
0 negative 0 
30 
west 
bengal 
6
6 m axillary - - - 1 diffuse centroblastic 1 2 1 0 0 2 0 2 1 2 diffuse 90 - 0 
31 
tamil 
nadu 
5
6 f retroperitoneal 1 IVB 
2
/
5 1 diffuse centroblastic 2 1 0 1 0 2 0 1 N/A 2 diffuse 70 - 0 
32 bihar 
6
3 m mediastinal 1 IB 
4
/
5 0 diffuse centroblastic 1 0 0 0 0 1 1 2 N/A 1 diffuse 90 - 
very 
occasional  
33 
chattis
garh 
5
4 m right axillary 1 - - 0 diffuse centroblastic 2 1 0 1 0 2 0 1 0 2 diffuse 60 - 0 
34 - 
5
1 f left cervical - - - - diffuse centroblastic 1 1 2 1 0 2 0 1 1 3 diffuse 80 negative 0 
35 
west 
bengal 
5
2 f right axillary 1 - - 0 diffuse  centroblastic 2 2 2 0 0 2 0 1 1 1 diffuse 80 - 0 
36 
west 
bengal 
5
0 m left cervical 1 IIIBX 
2
/
5 0 diffuse 
centroblastic, but with 
many immunoblasts 2 1 0 0 0 2 0 2 1 1 diffuse 90 - 0 
37 
west 
bengal 
5
1 m left cervical 1 IIIBS 
3
/
5 0 diffuse centroblastic 2 0 0 1 0 2 0 0 1 1 diffuse 90 - 5-10 
38 
tamil 
nadu 
7
2 f left groin 0 IIAX 
3
/
5 - diffuse 
centroblastic with 
clear cells 2 2 1 0 0 2 0 2 N/A 2 diffuse 
80
-
85 - 0 
39 
west 
bengal 
5
2 m left cervical 1 IIB 
0
/
5 0 diffuse 
centroblastic with 
clear cells 2 1 0 0 0 0 0 2 1 
N
/
A diffuse 80 - 0 
40 
jharka
nd 
6
2 f left cervical 1 IIIBX 
4
/
5 0 diffuse centroblastic 2 1 1 1 0 2 0 1 1 1 diffuse 
70
-
80 - 0 
41 
andhra 
prades
h 
6
3 m right cervical - - - - diffuse centroblastic 1 2 1 1 0 2 0 0 1 1 diffuse 
90
-
95 - 0 
42 nepal 
6
5 m retroperitoneal - - - 0 diffuse 
centroblastic, but with 
many immunoblasts 2 0 1 1 0 2 0 0 N/A 1 diffuse 80 - 0 
43 
west 
bengal 
4
8 f abdominal  - IV  - - nodular centroblastic 
2 
marked 0 0 0 0 1 0 0 N/A 1 nodular 90 - 0 
44 
andhra 
prades
h 
4
8 f 
left inguinal (gen 
LN pathy) - - - - diffuse centroblastic 1 1 2 1 1 1 0 0 N/A - diffuse 70 negative N/A 
45 
bangla
desh 
8
3 m cervical - - - - diffuse centroblastic 2 1 1 1 0 2 0 0 1 2 diffuse 90 - 0 
46 
tamil 
nadu 
6
1 m 
right inguinal 
(multiple lymph 
nodes) 0 IVA 
3
/
5 1 diffuse 
centroblastic, but with 
many immunoblasts 2 0 1 1 0 2 0 0 N/A - - 
70
-
80 - 0 
47 
tamil 
nadu 
6
3 f diffuse 0 IIIAE 
4
/
5 0 scattered centroblastic 2 1 1 1 0 2 0 1 1 1 
diffuse and 
scattered 70 - 0 
48 
tamil 
nadu 
6
9 f 
right 
submandibular 0 IIA 
1
/
5 0 
vague 
nodular centroblastic 
2 
marked 0 2 1 0 2 0 0 1 3 
diffuse and 
scattered 80 - 
very 
occasional  
49 
west 
bengal 
5
7 m right iliac - - - - diffuse centroblastic 2 0 0 0 0 0 0 1 N/A 2 diffuse 
30
-
40 - 0 
50 
west 
bengal 
5
9 m left cervical - - - 0 diffuse centroblastic 1 1 0 0 0 2 0 2 N/A 1 diffuse 60 - 
very 
occasional  
51 
bangla
desh 
5
5 f left cervical 1 - - 0 diffuse centroblastic 1 1 0 0 0 2 0 0 N/A 1 diffuse 
>9
0 - 0 
52 
west 
bengal 
7
0 m left axillary 1 
IIBE
X 
4
/
5 0 diffuse 
centroblastic with 
spindling 1 0 1 1 0 2 0 0 1 1 diffuse 80 - 
very 
occasional  
53 
manip
ur 
5
6 m ? 1 
IIBS
E - 0 diffuse centroblastic 2 0 0 0 0 2 0 0 1 1 diffuse 80 - 0 
54 
nagala
nd 
7
5 m 
left 
supraclavicular 1 IIIB 
2
/
5 0 diffuse 
centroblastic with 
clear cells 1 0 0 1 0 1 0 0 1 - - 80 positive 80-90 
55 kerala 
5
2 m left cervical 1 IIIBX 
3
/
5 0 diffuse centroblastic 2 2 0 0 0 0 0 0 0 1 - - 95 - 
56 
bangla
desh 
5
8 f ? 1 IIBE  
2
/
5 0 nodular centroblastic 2 0 1 1 0 1 0 0 focal 2 nodular 60 - 0 
 57 
west 
bengal 
5
4 m right axillary - - - 1 
vague 
nodular centroblastic 2 0 1 0 0 1 0 0 N/A 3 diffuse 
>9
0 - 0 
58 
west 
bengal 
5
9 m left cervical 0 IV  - 0 diffuse centroblastic 1 1 0 1 0 2 0 2 N/A 1 diffuse 
>9
0 - 0 
59 assam 
5
4 m inguinal - - - 0 
diffuse + 
vague 
nodular centroblastic 2 1 2 1 0 1 0 0 1 
N
/
A diffuse 
80
-
90 - 0 
60 - 
6
8 f 
right 
supraclavicular - - - - diffuse centroblastic 1 0 0 0 0 N/A 0 
N/
A 1 1 diffuse 70 - 0 
61 assam 
8
0 m right axillary 1 IIIB - 0 
diffuse+no
dular centroblastic 1 1 1 1 0 1 0 0 1 
N
/
A diffuse 
 
>9
0 - 80-90 
62 
jharka
nd 
6
4 m 
left inguinal (gen 
LN pathy) 0 IIAX 
3
/
5 0 diffuse centroblastic 2 0 2 0 0 2 0 1 1 - diffuse 40 - 0 
63 kerala 
5
1 f left axillary 1 IVB 
3
/
5 1 diffuse 
centroblastic, focal 
increase in 
immunoblasts 2 1 1 1 0 2 0 0 1 1 diffuse 
80
-
90 - 0 
64 assam 
6
8 m left cervical - - - - diffuse centroblastic 1 0 1 0 0 2 0 0 1 1 diffuse 
80
-
90 - 0 
65 
tamil 
nadu 
5
9 m right cervical 1 IVBS 
3
/
5 0 
diffuse + 
vague 
nodular centroblastic 2 1 2 1 0 1 0 0 1 1 diffuse 90 - 0 
66 
jharka
nd 
6
5 m right cervical - - - - diffuse centroblastic 1 0 0 0 0 1 0 0 1 2 diffuse 
90
-
95 - 0 
67 - 
5
5 m inguinal - - - - diffuse centroblastic 1 1 0 1 0 2 0 0 N/A 1 diffuse 80 - N/A 
68 
jharka
nd 
6
1 m right axillary 1 IIIB 
4
/
5 0 diffuse 
centroblastic, but with 
many immunoblasts 
(60%) 2 2 2 1 0 2 0 0 N/A 1 diffuse 
85
-
90 - 0 
69 
west 
bengal 
5
0 f left cervical 0 IIA 0 0 diffuse centroblastic 2 1 1 0 0 2 0 0 1 
N
/
A diffuse 
85
-
90 - 0 
70 
tamil 
nadu 
7
6 m cervical - - - - diffuse centroblastic 1 
N/
A 0 0 0 2 0 2 1 2 diffuse 80 - 0 
71 
karnata
ka 
5
4 f cervical - - - 0 N/A centroblastic 1 
N/
A 0 0 0 0 0 0 1 1 diffuse 
85
-
90 - 0 
72 
west 
bengal 
5
4 m 
left 
submandibular - - - 0 diffuse centroblastic 2 2 1 1 1 2 0 2 0 1 diffuse 
90
-
95 - 0 
73 
andhra 
prades
h 
5
0 f cervical - - - - diffuse 
centroblastic, focal 
increase in 
immunoblasts 2 0 1 1 0 2 0 0 1 1 diffuse 80 - 0 
74 assam 
6
1 m right axillary 1 - - 0 
diffuse + 
vague 
nodular 
centroblastic, but with 
many immunoblasts 2 0 0 0 0 2 0 0 1 1 diffuse 90 - 0 
75 
jharka
nd 
7
8 m left inguinal - - - - diffuse 
N/a- medium sized 
cells N/a 2 0 0 0 2 0 2 1 - - 70 - 0 
76 
tamil 
nadu 
5
6 m right cervical 0 IBEX - 0 diffuse centroblastic 1 0 0 0 0 2 0 0 1 - - 90 - 0 
77 - 
6
5 m ? - - - - 
diffuse+no
dular centroblastic 1 0 0 0 0 2 0 0 1 - - 80 - 0 
78 
west 
bengal 
5
2 m retroperitoneal - - - - diffuse centroblastic 1 2 0 0 0 2 0 
N/
A N/A 1 diffuse 
90
-
95 - 0 
79 
west 
bengal 
6
6 m abdominal  - - - - diffuse centroblastic 2 0 1 1 0 N/A 0 1 1 2 diffuse 
N/
A - N/A 
80 
west 
bengal 
7
0 f right cervical 1 IVB 
4
/
5 0 diffuse 
centroblastic, focal 
increase in 
immunoblasts 1 0 1 1 0 1 0 0 1 2 diffuse 80 0 
very 
occasional  
81 
west 
bengal 
6
4 m 
right 
submandibular - - - 0 diffuse centroblastic 2 2 1 1 0 2 0 0 1 1 diffuse 70 - 0 
82 
west 
bengal 
5
4 m right inguinal - - - 0 diffuse centroblastic 2 0 0 0 0 2 0 
N/
A 1 2 diffuse 
40
-
50 - 0 
83 
jharka
nd 
6
7 f 
right posterior 
cervical - - - 1 diffuse centroblastic 1 0 0 0 0 2 0 2 1 1 diffuse 60 - 0 
84 
west 
bengal 
6
1 m 
left 
submandibular 
(gen LN pathy) 1 IIB 1 0 diffuse centroblastic 1 1 0 0 0 0 0 0 1 1 diffuse 70 - 0 
85 
tamil 
nadu 
5
1 f mediastinal 1 - - 1 diffuse centroblastic 2 1 2 0 0 2 0 0 1 1 diffuse 90 0 N/A 
 86 
west 
bengal 
5
0 m left inguinal 0 - - 0 diffuse centroblastic 1 1 0 0 0 0 0 0 N/A 1 diffuse 
>9
0 - 0 
87 
andhra 
prades
h 
7
8 m 
left 
supraclavicular 1 IIIB 
3
/
5 0 diffuse centroblastic 2 2 2 1 0 0 0 0 1 1 diffuse 90 - - 
88 
tamil 
nadu 
5
6 f right cervical 0 IAE - 0 diffuse centroblastic 1 0 1 0 0 1 0 0 N/A 1 diffuse 
>9
5 - - 
89 
jharka
nd 
5
7 f left cervical 0 IVA - 1 diffuse centroblastic 1 2 1 0 0 1 0 0 1 1 diffuse 90 - - 
90 
west 
bengal 
7
6 m para-aortic - - - 0 diffuse centroblastic 0 0 0 0 0 2 0 2 N/A 2 diffuse 90 - - 
91 
andhra 
prades
h 
6
0 m right inguinal 0 IV 
5
/
5 - 
diffuse+no
dular centroblastic 2 2 0 1 0 1 0 1 0 1 diffuse 
>9
0 - - 
92 
west 
bengal 
5
0 m right cervical - - - 1 
vague 
nodular centroblastic 1 0 1 1 1 1 0 0 1 1 diffuse 70 - - 
93 
tamil 
nadu 
5
7 m 
right 
supraclavicular - - - 1 nodular centroblastic 2 1 0 0 0 2 0 0 1 1 diffuse 
>9
5 - - 
94 
west 
bengal 
7
1 m left cervical - - - 0 diffuse centroblastic 1 2 0 1 0 2 0 2 N/A 1 diffuse 
85
-
90 - - 
95 
bangla
desh 
5
3 m right inguinal - - - 0 diffuse centroblastic 1 1 1 0 0 2 0 1 1 1 diffuse 90 - - 
96 
andhra 
prades
h 
4
8 m 
left 
supraclavicular - - - - 
diffuse 
with 
sclerosis 
centroblastic with 
clear cells N/a 0 0 0 0 2 0 2 1 1 diffuse??? 
85
-
90 - - 
97 - 
6
7 m left inguinal - - - - diffuse 
centroblastic, but with 
many immunoblasts 2 1 2 0 0 2 0 1 1 2 diffuse 70 - - 
98 
tamil 
nadu 
5
6 m 
left 
supraclavicular - - - 0 nodular centroblastic 1 0 1 0 0 2 0 2 1 1 nodular patchy 90 - - 
99 
west 
bengal 
5
0 f right axillary 0 IIAE - 0 diffuse centroblastic 2 0 0 0 0 1 0 1 1 2 nodular 
70
-
80 - 0 
100 
tamil 
nadu 
5
7 f 
left 
supraclavicular - - - 0 
diffuse+no
dular centroblastic 2 0 0 1 0 2 0 2 1 2 diffuse 70 - 0 
101 
west 
bengal 
6
2 m left cervical - - - - diffuse centroblastic 2 0 0 0 0 2 N/A 1 1 2 diffuse 80 - 0 
102 
andhra 
prades
h 
5
0 f right axillary 1 IVB 
2
/
5 0 diffuse centroblastic 2 1 2 0 0 0 0 0 N/A 2 diffuse 
>9
0 - - 
103 
tamil 
nadu 
4
8 m left axillary - III - 0 diffuse centroblastic 
1 with 
eosinoph
ils 1 0 1 0 2 0 0 1 3 diffuse 70 - - 
104 assam 
5
1 m right inguinal 1 
IIBS
X - 0 diffuse centroblastic N/A 0 1 0 0 2 0 2 N/A 1 diffuse 70 - - 
105 
tamil 
nadu 
6
2 f retroperitoneal 0 IAEx 
3
/
5 0 diffuse centroblastic 2 1 0 0 0 0 0 1 N/A 1 diffuse 
50
-
60 - 0 
106 
jharka
nd 
5
8 m right cervical 1 IIIB - 0 diffuse centroblastic 2 2 2 1 0 2 0 0 1 1 diffuse 90 - 0 
107 
tamil 
nadu 
6
8 m 
left upper deep 
cervical 0 IIAE - 0 
diffuse+no
dular centroblastic 2 1 0 0 0 2 0 2 1 3 vague nodular 
60
-
70 ? Focal 0 
108 
west 
bengal 
4
9 m right inguinal - - - 1 
diffuse+no
dular 
centroblastic with 
clear cells 2 0 2 0 0 2 0 1 1 2 diffuse 
>9
0 - 0 
109 
tamil 
nadu 
8
0 m inguinal 1 - - 0 diffuse centroblastic 1 0 1 1 0 2 0 1 1 1 diffuse  90 - 0 
110 
west 
bengal 
7
5 m right cervical - - - - diffuse centroblastic 1 0 0 0 0 2 0 2 N/A 1 diffuse 
60
-
70 - 0 
111 
tamil 
nadu 
5
0 m right axillary - - - - diffuse centroblastic 1 
N/
A 0 1 0 1 0 1 1 2 patchy 90 - 60-80 
112 kerala 
6
3 m left inguinal 1 IVB 
5
/
5 0 
diffuse + 
vague 
nodular 
centroblastic, but with 
many immunoblasts 1 1 1 1 0 1 0 0 N/A 2 
loose 
aggregates and 
single cells 
70
-
80 focal 20-30 
113 
bangla
desh 
5
7 m right cervical - - - - 
vague 
nodular centroblastic 2 0 1 1 1 2 0 1 N/A 1 diffuse 
>9
5 - 0 
114 - 
7
1 f 
cervical 
(multiple LN) - - - - diffuse centroblastic 2 0 1 1 0 2 0 0 1 2 diffuse 
70
-
80 - 0 
115 
meghal
aya 
5
6 f cervical 1 IVB - 1 diffuse centroblastic 2 1 1 1 1 2 0 0 1 3 diffuse 
80
-
90 - 0 
 116 
west 
bengal 
6
0 m left axillary - - - - 
diffuse + 
vague 
nodular centroblastic 1 1 0 0 0 1 0 1 1 2 vague nodular 90 - 0 
117 
tamil 
nadu 
7
5 m retroperitoneal 0 II 
2
/
5 0 diffuse centroblastic 1 0 0 0 0 2 0 2 N/A 1 diffuse 
>9
5 - 0 
118 
west 
bengal 
5
3 f right cervical 0 IA - 0 diffuse centroblastic 0 2 1 1 0 2 0 0 1 1 diffuse 80 - 0 
119 
tamil 
nadu 
6
3 m 
left axillary 
(with gen LN) 1 IIIBX 
4
/
5 0 diffuse centroblastic 1 0 2 0 0 2 0 0 1 1 diffuse 
>9
0 - 0 
120 
bangla
desh 
5
0 m right inguinal 1 IVB 
3
/
5 1 diffuse centroblastic 1 0 0 0 0 2 0 0 N/A 1 diffuse 
80
-
90 - 0 
121 
west 
bengal 
7
2 m 
left 
supraclavicular 1 - - - diffuse centroblastic 1 0 0 0 0 2 0 0 0 1 diffuse 95 0 N/A 
122 
west 
bengal 
4
8 f left cervical - - - - diffuse centroblastic 1 2 0 0 0 2 0 1 1 1 diffuse 70 - 0 
123 
tamil 
nadu 
6
5 f axillary 1 - - 1 diffuse centroblastic 2 0 2 0 0 2 0 0 1 2 diffuse 
90
-
95 - 0 
124 
west 
bengal 
7
2 m right inguinal - - - 0 diffuse centroblastic 2 2 2 0 0 2 0 0 0 1 diffuse 
80
-
90 - 0 
125 assam 
5
9 f left cervical - IIIE - 0 diffuse centroblastic 1 0 0 0 0 2 0 0 minimal 
N
/
A diffuse 
80
-
90 - 0 
126 
jharka
nd 
5
0 m right inguinal 1 IIIB - 0 diffuse 
centroblastic, but with 
many immunoblasts 1 0 1 1 0 1 0 0 1 3 diffuse 
N/
A - 50-60 
127 kerala 
7
0 f axillary - - - 1 diffuse 
centroblastic, but with 
many immunoblasts 2 1 1 1 0 2 0 0 1 1 diffuse 80 - 0 
128 
west 
bengal 
6
2 m left axillary 1 - - - diffuse centroblastic 2 1 0 0 0 2 0 0 1 2 diffuse 
>9
5 - 0 
129 
west 
bengal 
6
7 m right cervical - - - 0 nodular 
centroblastic, but with 
many immunoblasts 2 0 0 1 1 2 0 1 1 3 
non uniform 
staining 80 - 0 
 
 
